Primerica (PRI) 10-Q 9 Nov 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Oct. 31, 2022
Cover [Abstract]
Entity Registrant Name	Primerica, Inc.
Entity Central Index Key	0001475922
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Trading Symbol	PRI
Amendment Flag	false
Entity Common Stock, Shares Outstanding		36,898,170
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity File Number	001-34680
Entity Tax Identification Number	27-1204330
Entity Current Reporting Status	Yes
Entity Address, Address Line One	1 Primerica Parkway
Entity Address, City or Town	Duluth
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30099
City Area Code	770
Local Phone Number	381-1000
Title of 12(b) Security	Common Stock
Security Exchange Name	NYSE
Entity Interactive Data Current	Yes
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Investments:
Fixed-maturity securities available-for-sale, at fair value (amortized cost: $2,779,015 in 2022 and $2,621,388 in 2021)	$ 2,457,989	$ 2,702,567
Fixed-maturity security held-to-maturity, at amortized cost (fair value: $1,320,222 in 2022 and $1,551,113 in 2021)	1,433,760	1,379,100
Short-term investments available-for-sale, at fair value (amortized cost: $0 in 2022 and $85,246 in 2021)		85,243
Equity securities, at fair value (historical cost: $29,424 in 2022 and $34,255 in 2021)	33,079	42,551
Trading securities, at fair value (cost: $4,335 in 2022 and $24,769 in 2021)	3,718	24,355
Policy loans and other invested assets	48,787	30,612
Total investments	3,977,333	4,264,428
Cash and cash equivalents	438,025	392,501
Accrued investment income	19,949	18,702
Reinsurance recoverables	4,033,897	4,268,419
Deferred policy acquisition costs, net	3,049,102	2,943,782
Renewal commissions receivable	198,027	231,751
Agent balances, due premiums and other receivables	266,831	257,675
Goodwill	127,707	179,154
Intangible assets	188,150	195,825
Income taxes	90,719	81,799
Operating lease right-of-use assets	42,343	47,942
Other assets	403,452	441,253
Separate account assets	2,206,608	2,799,992
Total assets	15,042,143	16,123,223
Liabilities:
Future policy benefits	7,314,688	7,138,649
Unearned and advance premiums	16,153	16,437
Policy claims and other benefits payable	496,563	585,382
Other policyholders’ funds	492,479	501,823
Note payable - Short term		15,000
Note payable - Long term	592,705	592,102
Surplus note	1,433,293	1,378,585
Income taxes	129,347	241,311
Operating lease liabilities	47,935	53,920
Other liabilities	611,646	615,710
Payable under securities lending	80,754	94,529
Separate account liabilities	2,206,608	2,799,992
Commitments and contingent liabilities (see Commitments and Contingent Liabilities note)
Total liabilities	13,422,171	14,033,440
Temporary Stockholders’ Equity
Redeemable noncontrolling interests in consolidated entities		7,271
Equity attributable to Primerica, Inc.:
Common stock ($0.01 par value; authorized 500,000 shares in 2022 and 2021; issued and outstanding 37,027 shares in 2022 and 39,368 shares in 2021)	370	394
Paid-in capital		5,224
Retained earnings	1,887,952	2,004,506
Accumulated other comprehensive income (loss), net of income tax:
Unrealized foreign currency translation gains (losses)	(15,437)	8,611
Net unrealized investment gains (losses) on available-for-sale securities	(252,913)	63,777
Total permanent stockholders’ equity	1,619,972	2,082,512
Total liabilities and temporary and permanent stockholders’ equity	$ 15,042,143	$ 16,123,223

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Investments:
Fixed-maturity security held to maturity, fair value	$ 1,320,222	$ 1,551,113
Equity securities, at fair value, historical cost	29,424	34,255
Trading securities, amortized cost	$ 4,335	$ 24,769
Equity attributable to Primerica, Inc.:
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	37,027,000	39,368,000
Common stock, shares outstanding	37,027,000	39,368,000
Fixed Maturities
Investments:
Fixed-maturity securities and Short-term investments available-for-sale, amortized cost	$ 2,779,015	$ 2,621,388
Trading securities, amortized cost	4,335	24,769
Short-Term Investments
Investments:
Fixed-maturity securities and Short-term investments available-for-sale, amortized cost	$ 0	$ 85,246

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income - Unaudited - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues:
Direct premiums	$ 810,079	$ 785,277	$ 2,417,639	$ 2,327,804
Ceded premiums	(404,870)	(401,295)	(1,223,804)	(1,211,117)
Net premiums	405,209	383,982	1,193,835	1,116,687
Commissions and fees	225,468	269,796	717,956	754,529
Investment income net of investment expenses	40,629	35,741	112,148	106,970
Interest expense on surplus note	(16,283)	(15,741)	(47,613)	(46,382)
Net investment income	24,346	20,000	64,535	60,588
Realized investment gains (losses)	292	1,730	924	3,762
Other investment gains (losses)	(2,991)	(320)	(4,765)	114
Investment gains (losses)	(2,699)	1,410	(3,841)	3,876
Other, net	20,965	18,051	60,709	49,958
Revenues	673,289	693,239	2,033,194	1,985,638
Benefits and expenses:
Benefits and claims	171,293	183,425	511,619	535,561
Amortization of deferred policy acquisition costs	90,925	62,214	262,367	182,604
Sales commissions	105,915	129,268	359,602	382,465
Insurance expenses	57,552	51,901	176,521	149,246
Insurance commissions	7,666	8,412	22,982	25,990
Contract acquisition costs	13,446	23,524	53,479	23,524
Interest expense	6,802	7,529	20,469	21,814
Goodwill impairment loss	60,000		60,000
Other operating expenses	73,791	79,864	239,952	219,559
Total benefits and expenses	587,390	546,137	1,706,991	1,540,763
Income before income taxes	85,899	147,102	326,203	444,875
Income taxes	34,092	35,663	90,069	107,403
Net income	51,807	111,439	236,134	337,472
Net income (loss) attributable to noncontrolling interests		(1,017)	(5,038)	(1,017)
Net income attributable to Primerica, Inc.	$ 51,807	$ 112,456	$ 241,172	$ 338,489
Earnings per share attributable to common stockholders:
Basic earnings per share	$ 1.38	$ 2.83	$ 6.26	$ 8.53
Diluted earnings per share	$ 1.37	$ 2.82	$ 6.24	$ 8.50
Weighted-average shares used in computing earnings per share:
Basic	37,438	39,561	38,342	39,516
Diluted	37,541	39,679	38,452	39,637

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Loss) - Unaudited - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 51,807	$ 111,439	$ 236,134	$ 337,472
Unrealized investment gains (losses) on available-for-sale securities:
Change in unrealized holding gains (losses) on available-for-sale securities	(97,516)	(13,796)	(401,335)	(52,669)
Reclassification adjustment for investment (gains) losses included in net income	(154)	(1,879)	(867)	(3,052)
Foreign currency translation adjustments:
Change in unrealized foreign currency translation gains (losses)	(18,086)	(5,892)	(24,048)	6,490
Total other comprehensive income (loss) before income taxes	(115,756)	(21,567)	(426,250)	(49,231)
Income tax expense (benefit) related to items of other comprehensive income (loss)	(20,504)	(3,386)	(85,512)	(12,294)
Other comprehensive income (loss), net of income taxes	(95,252)	(18,181)	(340,738)	(36,937)
Total comprehensive income (loss)	(43,445)	93,258	(104,604)	300,535
Net income (loss) attributable to noncontrolling interests		(1,017)	(5,038)	(1,017)
Comprehensive income (loss) attributable to Primerica, Inc.	$ (43,445)	$ 94,275	$ (99,566)	$ 301,552

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Redeemable Noncontrolling Interests in Consolidated Entities/Temporary Stockholders' Equity [Member]
Balance, beginning of period at Dec. 31, 2020		$ 393		$ 1,705,786	$ 129,706
Share-based compensation			$ 24,449
Net issuance of common stock		2	(2)
Repurchases of common stock			(6,993)
Net income (loss)	$ 338,489			338,489
Dividends				(55,951)
Change in foreign currency translation adjustment,net of income taxes					6,490
Change in net unrealized investment gains (losses) during the period, net of income taxes					(43,427)
Acquisition of noncontrolling interest						$ 8,437
Net income (loss) attributable to noncontrolling interests	(1,017)					(1,017)
Change in noncontrolling interests in consolidated entities, net						211
Balance, end of period at Sep. 30, 2021	$ 2,098,942	395	17,454	1,988,324	92,769	7,631
Dividends declared per share	$ 1.41
Balance, beginning of period at Jun. 30, 2021		394	12,880	1,894,539	110,950
Share-based compensation			4,662
Net issuance of common stock		1	(1)
Repurchases of common stock			(87)
Net income (loss)	$ 112,456			112,456
Dividends				(18,671)
Change in foreign currency translation adjustment,net of income taxes					(5,892)
Change in net unrealized investment gains (losses) during the period, net of income taxes					(12,289)
Acquisition of noncontrolling interest						8,437
Net income (loss) attributable to noncontrolling interests	(1,017)					(1,017)
Change in noncontrolling interests in consolidated entities, net						211
Balance, end of period at Sep. 30, 2021	$ 2,098,942	395	17,454	1,988,324	92,769	7,631
Dividends declared per share	$ 0.47
Balance, beginning of period at Dec. 31, 2021	$ 2,082,512	394	5,224	2,004,506	72,388	7,271
Share-based compensation			27,528
Net issuance of common stock		2	(2)
Repurchases of common stock		(26)	(34,983)	(294,332)
Net income (loss)	241,172			241,172
Dividends				(63,394)
Change in foreign currency translation adjustment,net of income taxes					(24,048)
Change in net unrealized investment gains (losses) during the period, net of income taxes					(316,690)
Net income (loss) attributable to noncontrolling interests	(5,038)					(5,038)
Redemption of noncontrolling interest in consolidated entities			2,233			(2,233)
Balance, end of period at Sep. 30, 2022	$ 1,619,972	370		1,887,952	(268,350)
Dividends declared per share	$ 1.65
Balance, beginning of period at Jun. 30, 2022		378		1,948,244	(173,098)	2,233
Share-based compensation			3,747
Repurchases of common stock		(8)	(5,980)	(91,528)
Net income (loss)	$ 51,807			51,807
Dividends				(20,571)
Change in foreign currency translation adjustment,net of income taxes					(18,086)
Change in net unrealized investment gains (losses) during the period, net of income taxes					(77,166)
Redemption of noncontrolling interest in consolidated entities			$ 2,233			$ (2,233)
Balance, end of period at Sep. 30, 2022	$ 1,619,972	$ 370		$ 1,887,952	$ (268,350)
Dividends declared per share	$ 0.55

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net income	$ 236,134	$ 337,472
Adjustments to reconcile net income to cash provided by (used in) operating activities:
Change in future policy benefits and other policy liabilities	125,302	334,566
Deferral of policy acquisition costs	(383,955)	(422,194)
Amortization of deferred policy acquisition costs	262,367	182,604
Change in income taxes	(39,270)	(17,267)
Investment (gains) losses	3,841	(3,876)
Accretion and amortization of investments	2,972	3,798
Depreciation and amortization	25,631	19,691
Change in reinsurance recoverables	209,984	(2,426)
Change in agent balances, due premiums and other receivables	(13,120)	(10,957)
Change in renewal commissions receivable	21,861	(14,532)
Trading securities sold, matured, or called (acquired), net	19,862	(10,528)
Share-based compensation	19,652	14,834
Goodwill impairment loss	60,000
Change in other operating assets and liabilities, net	17	23,936
Net cash provided by (used in) operating activities	551,278	435,121
Available-for-sale investments sold, matured or called:
Fixed-maturity securities — sold	23,140	99,401
Fixed-maturity securities — matured or called	283,292	340,074
Short-term investments — sold	28,251	10,089
Short-term investments — matured or called	85,302
Equity securities — sold	12	716
Equity securities — matured or called	3,000
Available-for-sale investments acquired:
Fixed-maturity securities	(471,323)	(603,146)
Short-term investments	(28,241)	(50,902)
Equity securities — acquired	(141)	(2,898)
Purchases of property and equipment and other investing activities, net	(23,950)	(21,432)
Cash collateral received (returned) on loaned securities, net	(13,775)	33,110
Sales (purchases) of short-term investments using securities lending collateral, net	13,775	(33,110)
Purchase of business, net of cash acquired	3,867	(494,459)
Net cash provided by (used in) investing activities	(96,791)	(722,557)
Cash flows from financing activities:
Dividends paid	(63,394)	(55,951)
Common stock repurchased	(324,354)
Proceeds from revolving credit facility		125,000
Payment on note issued to seller of business	(12,364)
Tax withholdings on share-based compensation	(4,989)	(6,573)
Finance leases	(195)	(201)
Net cash provided by (used in) financing activities	(405,296)	62,275
Effect of foreign exchange rate changes on cash	(3,667)	3,170
Change in cash and cash equivalents	45,524	(221,991)
Cash and cash equivalents, beginning of period	392,501	547,569
Cash and cash equivalents, end of period	$ 438,025	325,578
Non-cash financing activity:
Increase in note issued to seller of business		$ 15,000

Description of Business, Basis

Description of Business, Basis of Presentation, and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business, Basis of Presentation, and Summary of Significant Accounting Policies	(1) Description of Business, Basis of Presentation, and Summary of Significant Accounting Policies Description of Business . Primerica, Inc. (the “Parent Company”), together with its subsidiaries (collectively, “we”, “us” or the “Company”), is a leading provider of financial products to middle-income households in the United States and Canada through a network of independent contractor sales representatives (“independent sales representatives” or “independent sales force”). We assist our clients in meeting their needs for term life insurance, which we underwrite, and mutual funds, annuities, managed investments and other financial products, which we distribute primarily on behalf of third parties. We acquired 80 % of e-TeleQuote Insurance, Inc. and subsidiaries (collectively, “e-TeleQuote”) through our subsidiary, Primerica Health, Inc. (“Primerica Health”) on July 1, 2021 and acquired the remaining 20 % of e-TeleQuote on July 1, 2022 . e-TeleQuote markets Medicare-related insurance products underwritten by third-party health insurance carriers to eligible Medicare participants through its licensed health insurance agents. Refer to Note 14 (Acquisition) for more information regarding the acquisition of e-TeleQuote. Our other primary subsidiaries include the following entities: Primerica Financial Services, LLC (“PFS”), a general agency and marketing company; Primerica Life Insurance Company (“Primerica Life”), our principal life insurance company; Primerica Financial Services (Canada) Ltd., a holding company for our Canadian operations, which includes Primerica Life Insurance Company of Canada (“Primerica Life Canada”) and PFSL Investments Canada Ltd. (“PFSL Investments Canada”); and PFS Investments Inc. (“PFS Investments”), an investment products company and broker-dealer. Primerica Life, domiciled in Tennessee, owns National Benefit Life Insurance Company (“NBLIC”), a New York insurance company. Peach Re, Inc. (“Peach Re”) and Vidalia Re, Inc. (“Vidalia Re”) are special purpose financial captive insurance companies and wholly owned subsidiaries of Primerica Life. Peach Re and Vidalia Re have each entered into separate coinsurance agreements with Primerica Life whereby Primerica Life has ceded certain level-premium term life insurance policies to Peach Re and Vidalia Re (respectively, the “Peach Re Coinsurance Agreement” and the “Vidalia Re Coinsurance Agreement”). Basis of Presentation . We prepare our financial statements in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). These principles are established primarily by the Financial Accounting Standards Board (“FASB”). The accompanying unaudited condensed consolidated financial statements contain all adjustments, generally consisting of normal recurring accruals, which are necessary to fairly present the balance sheets as of September 30, 2022 and December 31, 2021, the statements of income, comprehensive income, and stockholders’ equity for the three and nine months ended September 30, 2022 and 2021, and cash flows for the nine months ended September 30, 2022 and 2021. Results of operations for interim periods are not necessarily indicative of results for the entire year or of the results to be expected in future periods. These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are sufficient to make the information not misleading. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto that are included in our Annual Report on Form 10-K for the year ended December 31, 2021 (“2021 Annual Report”). Use of Estimates. The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect financial statement balances, revenues and expenses and cash flows, as well as the disclosure of contingent assets and liabilities. Management considers available facts and knowledge of existing circumstances when establishing the estimates included in our financial statements. The most significant items that involve a greater degree of accounting estimates and actuarial determinations subject to change in the future are the valuation of investments, deferred policy acquisition costs (“DAC”), future policy benefit reserves and corresponding amounts recoverable from reinsurers, renewal commissions receivable, income taxes, and valuation of intangible assets and goodwill. Estimates for these and other items are subject to change and are reassessed by management in accordance with U.S. GAAP. Actual results could differ from those estimates. Consolidation. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and those entities required to be consolidated under U.S. GAAP. All material intercompany profits, transactions, and balances among the consolidated entities have been eliminated. Reclassifications. Certain reclassifications have been made to prior-period amounts to conform to current-period reporting classifications. These reclassifications had no impact on net income or total stockholders’ equity. Changes to Accounting Policies . All significant accounting policies remain unchanged from the 2021 Annual Report unless otherwise described. Future Application of Accounting Standards. In August 2018, the FASB issued Accounting Standards Update No. 2018-12 , Financial Services—Insurance (Topic 944) — Targeted Improvements to the Accounting for Long-Duration Contracts (“ASU 2018-12” or “LDTI”). The amendments in this update change accounting guidance for insurance companies that issue long-duration contracts, including term life insurance . ASU 2018-12 requires companies that issue long-duration insurance contracts to update assumptions used in measuring future policy benefits and DAC, including mortality, disability, and persistency, at least annually instead of locking those assumptions at contract inception and reflecting differences in assumptions and actual performance as the experience occurs. ASU 2018-12 also changes how insurance companies that issue long-duration contracts amortize DAC and determine and update the discount rate assumptions used in measuring future policy benefits reserves while increasing the level of financial statement disclosures required. The guidance in ASU 2018-12 will be applied to the earliest period presented in the consolidated financial statements beginning on the effective date of January 1, 2023. The adoption of ASU 2018-12 will have an impact on our consolidated financial statements and related disclosures and will require changes to certain of our processes, systems, and controls. We are continuing to evaluate the impact the adoption will have on our consolidated financial statements. We are working on model refinement and model governance, finalizing actuarial assumptions and documenting our control process. Below is a list of topics relevant to the adoption of ASU 2018-12 and the expected impact on the Company. Topic Description Planned Approach Transition Approach LDTI guidance can be applied using either: • the retrospective method, which applies the provisions of the standard from the original policy inception; or • the modified retrospective method, which applies the provisions of the standard by pivoting off the historical December 31, 2020 future policy benefits reserve (“Pre-transition Reserve”) and deferred acquisition costs (“DAC”) balances just prior to January 1, 2021 (the “Transition Date”). The Company will elect to adopt the standard using the modified retrospective method for both future policy benefits reserves and amortization of DAC. The Company will adopt the standard effective January 1, 2023. Cohort Definition Cohorts refer to the level of policy grouping used in the calculation of the future policy benefits reserve (“FPBR”) and amortization of DAC. Under LDTI, cohorts must vary by policy issue year and may be set more granularly to reflect additional policy characteristics. The net premium ratio for each policy cohort is used to calculate FPBR. At the Transition Date, the Net Premium Ratio is defined as the present value of future benefits and claim settlement expenses less the Pre-transition Reserve divided by the present value of the gross premiums. The present value of both the future benefits and gross premiums use best estimate cash flow assumptions at the locked-in discount rate (discount rate at the Transition Date). Under LDTI, a cohort’s Net Premium Ratio is capped at 100 %. This concept replaces the need for loss recognition analysis under current GAAP. Any adjustments necessary at the Transition Date to cap the Net Premium Ratio for a cohort at 100 % are recognized in retained earnings. After the Transition Date, the Net Premium Ratio will be updated each quarter as projected benefits and premiums are replaced with actual amounts. The Company will define its Term Life Insurance segment cohorts based on the legal entity that issued the policy and the year the policy was issued. The Company expects the impact as of the Transition Date of capping the Net Premium Ratio at 100 % to be less than 3 % of total retained earnings. The identified impact from capping the Net Premium Ratio at 100 % is primarily attributable to a limited amount of older policy year cohorts. Discount Rates LDTI requires entities to use market observable rates, based on an upper-medium grade fixed income instrument yield, to measure future policy benefits reserves each period. The difference between the FPBR calculated using market observable rates and the Pre-transition Reserve is recognized as part of accumulated other comprehensive income (“AOCI”) at the Transition Date. After the Transition Date, the impact of changes in market observable rates each quarter will be recorded to AOCI and may add volatility to our reported equity. The Company will use discount rates applied by geography to align with local currency cash flows. Discount rates will consist of yield curves that will be developed using Bloomberg’s Evaluated Pricing Product (BVAL) based on senior unsecured fixed rate bonds ratings of A+, A or A-. Given how low market observable rates were at the Transition Date, we expect that the amount recorded in AOCI as of the Transition Date will reduce our AOCI and equity balances by approximately $ 1.2 to $ 1.5 billion, net of income tax. As of September 30, 2022, market observable rates have increased relative to the Transition Date, which will significantly reduce the AOCI impact in equity on our current balance sheet. If we were to apply market observable rates as of September 30, 2022 to the FPBR as of the Transition Date, the impact on AOCI would be between a $ 150 million increase and a $ 150 million decrease on an after-tax basis. Cash Flow Assumptions LDTI requires entities to use their best estimates for cash flow assumptions with no provision for adverse deviation. Cash flow assumptions are to be reviewed at least annually at the same time each year, or more frequently if experience suggests. Forecasted cash flow assumptions must be replaced with actual cash flows in FPBR at least annually. The Company expects to formally review cash flow assumptions during the third quarter each year and update these assumptions as necessary. The Company will replace forecasted cash flow assumptions with actual cash flows in FPBR each quarter. The impact of assumption changes and experience variances will be partly reflected in the current period and partly spread to future periods, based on the remaining duration of the impacted cohort(s), by unlocking the Net Premium Ratio in FPBR. DAC Amortization LDTI requires DAC to be amortized on a constant-level basis over the expected term of the contracts using an appropriate unit of measure. Companies can amortize DAC either at an individual contract level on a straight-line basis or at a cohort level that approximates a straight-line basis. Under current GAAP, DAC is amortized using amortization models linked to revenue or profit. Also, interest is accrued on unamortized DAC under current GAAP while LDTI disallows the accrual of interest. The Company anticipates it will use current face amount as a unit of measure to amortize DAC for its term life insurance products and policy count as a unit of measure to amortize DAC for its Canadian segregated funds products. In addition, the Company expects to group contracts by cohort to amortize DAC. For term life insurance products, we expect DAC to be amortized more slowly under LDTI as compared with current GAAP. For Canadian segregated funds, we expect DAC amortization to be less volatile than under current GAAP as it will no longer be based on the present value of gross profits, which are subject to changes in the market value of assets under management. Market Risk Benefits (“MRBs”) MRBs are benefits that protect policyholders from capital market risk. Under LDTI, MRBs are measured at fair value. The Company has MRBs from limited guaranteed benefits provided as part of our Canadian segregated funds products. We are still undergoing the process of evaluating MRBs associated with our Canadian segregated funds products but we currently anticipate that the fair value of MRBs associated with this product will be immaterial when LDTI is adopted. Recently-issued accounting guidance not discussed above is not applicable, is not material to our unaudited condensed consolidated financial statements, or did not or is not expected to have a material impact on our business.

Segment and Geographical Inform

Segment and Geographical Information	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Segment and Geographical Information	(2) Segment and Geographical Information Segments. We have three primary operating segments — Term Life Insurance, Investment and Savings Products, and (as of July 1, 2021) Senior Health. We also have a Corporate and Other Distributed Products segment. Notable information included in profit or loss by segment was as follows: Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 (In thousands) Revenues: Term life insurance segment $ 427,830 $ 401,451 $ 1,256,967 $ 1,167,016 Investment and savings products segment 201,697 233,337 665,152 694,770 Senior health segment 17,184 22,936 34,828 22,936 Corporate and other distributed products segment 26,578 35,515 76,247 100,916 Total revenues $ 673,289 $ 693,239 $ 2,033,194 $ 1,985,638 Net investment income: Term life insurance segment $ 13,241 $ 9,320 $ 36,973 $ 26,324 Investment and savings products segment - - - - Senior health segment - - - - Corporate and other distributed products segment 11,105 10,680 27,562 34,264 Total net investment income $ 24,346 $ 20,000 $ 64,535 $ 60,588 Amortization of DAC: Term life insurance segment $ 88,275 $ 59,287 $ 249,826 $ 174,106 Investment and savings products segment 2,222 2,580 11,610 7,641 Senior health segment - - - - Corporate and other distributed products segment 428 347 931 857 Total amortization of DAC $ 90,925 $ 62,214 $ 262,367 $ 182,604 Non-cash share-based compensation expense: Term life insurance segment $ 645 $ 570 $ 3,388 $ 3,303 Investment and savings products segment 672 665 2,559 2,532 Senior health segment 67 - 67 - Corporate and other distributed products segment ( 324 ) ( 594 ) 13,638 8,999 Total non-cash share-based compensation expense $ 1,060 $ 641 $ 19,652 $ 14,834 Income (loss) before income taxes: Term life insurance segment $ 111,764 $ 107,589 $ 323,220 $ 312,603 Investment and savings products segment 58,377 69,368 181,913 203,885 Senior health segment ( 63,723 ) ( 8,490 ) ( 102,959 ) ( 8,490 ) Corporate and other distributed products segment ( 20,519 ) ( 21,365 ) ( 75,971 ) ( 63,123 ) Total income (loss) before income taxes $ 85,899 $ 147,102 $ 326,203 $ 444,875 Total assets by segment were as follows: September 30, 2022 December 31, 2021 (In thousands) Assets: Term life insurance segment $ 7,164,005 $ 7,274,820 Investment and savings products segment (1) 2,324,810 2,920,271 Senior health segment 428,317 528,974 Corporate and other distributed products segment 5,125,011 5,399,158 Total assets $ 15,042,143 $ 16,123,223 (1) The Investment and Savings Products segment includes assets held in separate accounts. Excluding separate accounts, the Investment and Savings Products segment assets were $ 118.2 million and $ 120.3 million as of September 30, 2022 and December 31, 2021 , respectively. Geographical Information. Results of operations by country and long-lived assets, primarily tangible assets reported in other assets in our unaudited condensed consolidated balance sheets and condensed consolidated statements of income, were as follows: Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 (In thousands) Revenues by country: United States $ 588,954 $ 594,406 $ 1,750,621 $ 1,687,868 Canada 84,335 98,833 282,573 297,770 Total revenues $ 673,289 $ 693,239 $ 2,033,194 $ 1,985,638 September 30, 2022 December 31, 2021 (In thousands) Long-lived assets by country: United States $ 51,147 $ 62,921 Canada 3,111 3,871 Other 233 230 Total long-lived assets $ 54,491 $ 67,022

Investments

Investments	9 Months Ended
	Sep. 30, 2022
Investments Debt And Equity Securities [Abstract]
Investments	(3) Investments Available-for-sale Securities. The period-end amortized cost, gross unrealized gains and losses, and fair value of available-for-sale securities were as follows: September 30, 2022 Amortized cost Gross unrealized gains Gross unrealized losses Fair value (In thousands) Securities available-for-sale, carried at fair value: Fixed-maturity securities: U.S. government and agencies $ 32,698 $ 20 $ ( 980 ) $ 31,738 Foreign government 150,507 474 ( 11,037 ) 139,944 States and political subdivisions 142,852 59 ( 21,789 ) 121,122 Corporates 1,668,098 1,985 ( 194,251 ) 1,475,832 Residential mortgage-backed securities 477,103 251 ( 65,328 ) 412,026 Commercial mortgage-backed securities 139,940 3 ( 14,204 ) 125,739 Other asset-backed securities 167,817 - ( 16,229 ) 151,588 Total fixed-maturity securities 2,779,015 2,792 ( 323,818 ) 2,457,989 December 31, 2021 Amortized cost Gross unrealized gains Gross unrealized losses Fair value (In thousands) Securities available-for-sale, carried at fair value: Fixed-maturity securities: U.S. government and agencies $ 32,292 $ 187 $ ( 79 ) $ 32,400 Foreign government 147,288 6,283 ( 595 ) 152,976 States and political subdivisions 147,455 6,326 ( 254 ) 153,527 Corporates 1,649,334 72,418 ( 8,068 ) 1,713,684 Residential mortgage-backed securities 373,753 5,108 ( 3,230 ) 375,631 Commercial mortgage-backed securities 142,631 3,314 ( 420 ) 145,525 Other asset-backed securities 128,635 1,409 ( 1,220 ) 128,824 Total fixed-maturity securities 2,621,388 95,045 ( 13,866 ) 2,702,567 Short-term investments 85,246 1 ( 4 ) 85,243 Total fixed-maturity and short-term investments $ 2,706,634 $ 95,046 $ ( 13,870 ) $ 2,787,810 All of our available-for-sale mortgage- and asset-backed securities represent variable interests in variable interest entities (“VIEs”). We are not the primary beneficiary of these VIEs because we do not have the power to direct the activities that most significantly impact the entities’ economic performance. The maximum exposure to loss as a result of our involvement in these VIEs equals the carrying value of the securities. The scheduled maturity distribution of the available-for-sale fixed-maturity portfolio as of September 30, 2022 was as follows: Amortized cost Fair value (In thousands) Due in one year or less $ 185,346 $ 184,509 Due after one year through five years 768,889 724,190 Due after five years through 10 years 747,297 627,289 Due after 10 years 292,623 232,648 1,994,155 1,768,636 Mortgage- and asset-backed securities 784,860 689,353 Total AFS fixed-maturity securities $ 2,779,015 $ 2,457,989 Expected maturities may differ from scheduled contractual maturities because issuers of securities may have the right to call or prepay obligations with or without call or prepayment penalties. Trading Securities. The cost and fair value of the securities classified as trading securities were as follows: September 30, 2022 December 31, 2021 Cost Fair value Cost Fair value (In thousands) Fixed-maturity securities $ 4,335 $ 3,718 $ 24,769 $ 24,355 Held-to-maturity Security. Concurrent with the execution of the Vidalia Re Coinsurance Agreement, Vidalia Re entered into a Surplus Note Purchase Agreement (the “Surplus Note Purchase Agreement”) with Hannover Life Reassurance Company of America and certain of its affiliates (collectively, “Hannover Re”) and a newly formed limited liability company (the “LLC”) owned by a third- party service provider. Under the Surplus Note Purchase Agreement, Vidalia Re issued a surplus note (the “Surplus Note”) to the LLC in exchange for a credit enhanced note from the LLC with an equal principal amount (the “LLC Note”). The principal amount of both the LLC Note and the Surplus Note will fluctuate over time to coincide with the amount of reserves contractually supported under the Vidalia Re Coinsurance Agreement. Both the LLC Note and the Surplus Note mature on December 31, 2030 and bear interest at an annual interest rate of 4.50 % . The LLC Note is guaranteed by Hannover Re through a credit enhancement feature in exchange for a fee, which is reflected in interest expense on our unaudited condensed consolidated statements of income. The LLC is a VIE as its owner does not have an equity investment at risk that is sufficient to permit the LLC to finance its activities without Vidalia Re or Hannover Re. The Parent Company, Primerica Life, and Vidalia Re share the power to direct the activities of the LLC with Hannover Re, but do not have the obligation to absorb losses or the right to receive any residual returns related to the LLC’s primary risks or sources of variability. Through the credit enhancement feature, Hannover Re is the ultimate risk taker in this transaction and bears the obligation to absorb the LLC’s losses in the event of a Surplus Note default in exchange for the fee. Accordingly, the Company is not the primary beneficiary of the LLC and does not consolidate the LLC within its unaudited condensed consolidated financial statements. See Note 5 (Reinsurance) for Hannover Re’s financial strength rating. The LLC Note is classified as a fixed-maturity held-to-maturity security in the Company’s invested asset portfolio as we have the positive intent and ability to hold the security until maturity. As of September 30, 2022, the LLC Note had an estimated unrealized holding loss of $ 113.5 million based on its amortized cost and estimated fair value. The estimated fair value of the LLC Note is expected to be at least equal to the estimated fair value of the offsetting Surplus Note. See Note 12 (Debt) for more information on the Surplus Note. As of September 30, 2022 , no credit losses have been recognized on the LLC Note. Investments on Deposit with Governmental Authorities. As required by law, we have investments on deposit with governmental authorities and banks for the protection of policyholders. The fair values of investments on deposit were $ 7.1 million and $ 7.6 million as of September 30, 2022 and December 31, 2021, respectively. Securities Lending Transactions. We participate in securities lending transactions with broker-dealers and other financial institutions to increase investment income with minimal risk. We require minimum collateral on securities loaned equal to 102 % of the fair value of the loaned securities. We accept collateral in the form of securities, which we are not able to sell or encumber, and to the extent the collateral declines in value below 100 %, we require additional collateral from the borrower. Any securities collateral received is not reflected on our unaudited condensed consolidated balance sheets. We also accept collateral in the form of cash, all of which we reinvest. For loans involving unrestricted cash collateral, the collateral is reported as an asset with a corresponding liability representing our obligation to return the collateral. We continue to carry the loaned securities as invested assets on our unaudited condensed consolidated balance sheets during the terms of the loans, and we do not report them as sales. Cash collateral received and reinvested was $ 80.8 million and $ 94.5 million as of September 30, 2022 and December 31, 2021, respectively. Investment Income. The components of net investment income were as follows: Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 (In thousands) Fixed-maturity securities (available-for-sale) $ 23,067 $ 19,860 $ 66,370 $ 60,035 Fixed-maturity security (held-to-maturity) 16,283 15,741 47,613 46,382 Equity securities 373 413 1,131 1,216 Policy loans and other invested assets 436 289 596 618 Cash and cash equivalents 1,714 96 2,338 371 Total return on deposit asset underlying 10% coinsurance agreement (1) 489 346 ( 1,790 ) 1,989 Gross investment income 42,362 36,745 116,258 110,611 Investment expenses ( 1,733 ) ( 1,004 ) ( 4,110 ) ( 3,641 ) Investment income net of investment expenses 40,629 35,741 112,148 106,970 Interest expense on surplus note ( 16,283 ) ( 15,741 ) ( 47,613 ) ( 46,382 ) Net investment income $ 24,346 $ 20,000 $ 64,535 $ 60,588 (1) For the three months ended September 30, 2022, includes less than ($ 0.1 ) million of net losses recognized for the change in fair value of the deposit asset underlying the 10 % coinsurance agreement. For the nine months ended September 30, 2022, includes $( 3.4 ) million of net losses recognized for the change in fair value of the deposit asset underlying the 10 % coinsurance agreement. For the three and nine months ended September 30, 2021, includes $( 0.6 ) million and $( 1.6 ) million, respectively, of net losses recognized for the change in fair value of the deposit asset underlying the 10 % coinsurance agreement. The components of investment gains (losses), as well as details on gross realized investment gains (losses) and other investment gains (losses) were as follows: Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 (In thousands) Realized investment gains (losses): Gross gains from sales of available-for-sale securities fixed maturity securities $ 491 $ 1,801 $ 1,512 $ 5,780 Gross losses from sales of available-for-sale fixed maturity securities ( 199 ) ( 71 ) ( 588 ) ( 2,018 ) Net realized investment gains (losses): 292 1,730 924 3,762 Other investment gains (losses): Credit losses impairment of available-for-sale securities ( 138 ) 149 ( 57 ) ( 710 ) Market gains (losses) recognized in net income during the period on equity securities ( 2,858 ) ( 418 ) ( 4,692 ) 1,117 Gains (losses) from bifurcated options - 1 - ( 48 ) Gains (losses) on trading securities 5 ( 52 ) ( 16 ) ( 245 ) Other investment gains (losses): ( 2,991 ) ( 320 ) ( 4,765 ) 114 Investment gains (losses) $ ( 2,699 ) $ 1,410 $ ( 3,841 ) $ 3,876 The proceeds from sales or other redemptions of available-for-sale securities were as follows: Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 (In thousands) Proceeds from sales or other redemptions $ 117,909 $ 135,393 $ 419,985 $ 449,564 Accrued Interest. Accrued interest is recorded in accordance with the original interest schedule of the underlying security. In the event of default, the Company’s policy is to no longer accrue interest on these securities and any remaining accrued interest will be written off. As a result, the Company has made the policy election to not record an allowance for credit losses on accrued interest. Credit Losses for Available-for-sale Securities. The following table summarizes all available-for-sale securities in an unrealized loss position for which an allowance for credit losses has not been recorded as of September 30, 2022, aggregated by major security type and length of time such securities have continuously been in an unrealized loss position: September 30, 2022 Less than 12 months 12 months or longer Fair value Unrealized losses Fair value Unrealized losses (Dollars in thousands) Fixed-maturity securities: U.S. government and agencies $ 27,735 $ ( 744 ) $ 2,170 $ ( 236 ) Foreign government 114,843 ( 7,332 ) 17,132 ( 3,705 ) States and political subdivisions 105,750 ( 18,900 ) 11,798 ( 2,889 ) Corporates 1,202,033 ( 127,943 ) 239,948 ( 66,308 ) Residential mortgage-backed securities 301,304 ( 41,127 ) 103,895 ( 24,201 ) Commercial mortgage-backed securities 96,986 ( 10,949 ) 28,352 ( 3,255 ) Other asset-backed securities 102,080 ( 8,368 ) 49,508 ( 7,861 ) Total fixed-maturity securities 1,950,731 ( 215,363 ) 452,803 ( 108,455 ) December 31, 2021 Less than 12 months 12 months or longer Fair value Unrealized losses Fair value Unrealized losses (Dollars in thousands) Fixed-maturity securities: U.S. government and agencies $ 24,928 $ ( 45 ) $ 1,557 $ ( 34 ) Foreign government 18,894 ( 384 ) 3,335 ( 211 ) States and political subdivisions 15,909 ( 254 ) - - Corporates 341,963 ( 5,035 ) 59,414 ( 3,033 ) Residential mortgage-backed securities 234,911 ( 3,131 ) 2,707 ( 99 ) Commercial mortgage-backed securities 47,220 ( 419 ) 117 ( 1 ) Other asset-backed securities 80,509 ( 1,037 ) 3,779 ( 183 ) Total fixed-maturity securities 764,334 ( 10,305 ) 70,909 ( 3,561 ) Short-term investments: U.S. government and agencies 34,967 * - - Foreign government 4,995 * - - States and political subdivisions 11,394 ( 1 ) - - Corporates 23,891 ( 3 ) - - Total short-term investments 75,247 ( 4 ) - - Total fixed-maturity securities and short-term investments $ 839,581 $ ( 10,309 ) $ 70,909 $ ( 3,561 ) * Less than $ 1 thousand. The amortized cost of available-for-sale fixed-maturity securities with a cost basis in excess of their fair values were $ 2.7 billion and $ 924.4 million as of September 30, 2022 and December 31, 2021, respectively. As of September 30, 2022, we did not recognize credit losses in the unaudited condensed consolidated statements of income on available-for-sale securities with unrealized losses that were due to interest rate sensitivity and changes in credit spreads. We believe that fluctuations caused by movement in interest rates and credit spreads generally have little bearing on the recoverability of our investments. For those that remain in an unrealized loss position we have the ability to hold these investments until maturity or a market price recovery, and we have no present intention to dispose them. The sharp increase in interest rates during the three and nine months ended September 30, 2022 was the primary driver of the increase in unrealized losses on available-for-sale securities. For the three months ended September 30, 2022, we recognized $ 0.1 million of credit (gains) losses in the unaudited condensed consolidated statements of income on available-for-sale securities. For the nine months ended September 30, 2022, we recorded less than $ 0.1 million for credit (gains) losses in the unaudited condensed consolidated statements of income on available-for-sale securities. For the three and nine months ended September 30, 2021, we recorded a total of $( 0.1 ) million and $ 0.7 million, respectively, for credit (gains) losses in the unaudited condensed consolidated statements of income on available-for-sale securities. We recognized credit losses on securities due to: (i) our intent to sell them; (ii) adverse credit events indicating that we will not receive the security’s contractual cash flows when contractually due, such as news of an impending filing for bankruptcy; (iii) analyses of the issuer’s most recent financial statements or other information indicating that significant liquidity deficiencies, significant losses and large declines in capitalization exist; and (iv) analyses of rating agency information for issuances with severe ratings downgrades indicating a significant increase in the possibility of default. The rollforward of the allowance for credit losses on available-for-sale securities were as follows: Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 (In thousands) Allowance for credit losses, beginning of period $ - $ 858 $ 816 $ - Additions to the allowance for credit losses on securities for which credit losses were not previously recorded - 6 - 160 Additional increases or (decreases) to the allowance for credit losses on securities that had an allowance recorded in a previous period - ( 154 ) ( 81 ) 550 Write-offs charged against the allowance, if any - - ( 735 ) - Allowance for credit losses, end of period $ - $ 710 $ - $ 710 Derivatives. We carry a deferred loss related to closed forward contracts, which were settled several years ago, that were used to mitigate our exposure to foreign currency exchange rates that resulted from the net investment in our Canadian operations. The amount of deferred loss included in accumulated other comprehensive income was $ 26.4 million as of September 30, 2022 and December 31, 2021 . These deferred losses will not be recognized until such time as we sell or substantially liquidate our Canadian operations. We have no such intention.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	(4) Fair Value of Financial Instruments Fair value is the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Invested assets recorded at fair value are measured and classified in accordance with a three-tier fair value hierarchy based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market assumptions in the absence of observable market information. We classify and disclose all invested assets carried at fair value in one of the following three levels: • Level 1. Quoted prices for identical instruments in active markets. Level 1 consists of financial instruments whose value is based on quoted market prices in active markets, such as cash, cash equivalents in money market funds, exchange-traded common stocks and actively traded mutual fund investments; • Level 2. Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. Level 2 includes those financial instruments that are valued using industry-standard pricing methodologies, models or other valuation methodologies. Various inputs are considered in deriving the fair value of the underlying financial instrument, including interest rate and yield curves, credit spread, and foreign exchange rates. All significant inputs are observable, or derived from observable information in the marketplace or are supported by observable levels at which transactions are executed in the marketplace. Financial instruments in this category primarily include: cash equivalents and short-term investments in U.S. treasury securities, certain public and private corporate fixed-maturity and equity securities; government or agency securities; and certain mortgage- and asset-backed securities; and • Level 3. Valuations derived from valuation techniques in which one or more significant inputs are unobservable. Level 3 consists of financial instruments whose fair value is estimated based on industry-standard pricing methodologies and models using significant inputs not based on, nor corroborated by, readily available market information. Valuations for this category primarily consist of non-binding broker quotes. Financial instruments in this category primarily include less liquid mortgage- and asset-backed securities and equity securities. As of each reporting period, all assets and liabilities recorded at fair value are classified in their entirety based on the lowest level of input (Level 3 being the lowest in the hierarchy) that is significant to the fair value measurement. Significant levels of estimation and judgment are required to determine the fair value of certain of our investments. The factors influencing these estimations and judgments are subject to change in subsequent reporting periods. The estimated fair value and hierarchy classifications for assets and liabilities that are measured at fair value on a recurring basis were as follows: September 30, 2022 Level 1 Level 2 Level 3 Total (In thousands) Fair value assets: Available-for-sale fixed-maturity securities: U.S. government and agencies $ - $ 31,738 $ - $ 31,738 Foreign government - 139,944 - 139,944 States and political subdivisions - 121,122 - 121,122 Corporates 3,811 1,472,021 - 1,475,832 Mortgage- and asset-backed securities: Residential mortgage-backed securities - 408,228 3,798 412,026 Commercial mortgage-backed securities - 124,741 998 125,739 Other asset-backed securities - 150,214 1,374 151,588 Total available-for-sale fixed-maturity securities 3,811 2,448,008 6,170 2,457,989 Short-term investments - - - - Total available-for-sale securities 3,811 2,448,008 6,170 2,457,989 Equity securities 30,577 988 1,514 33,079 Trading securities - 3,718 - 3,718 Cash and cash equivalents 438,025 - - 438,025 Separate accounts - 2,206,608 - 2,206,608 Total fair value assets $ 472,413 $ 4,659,322 $ 7,684 $ 5,139,419 Fair value liabilities: Separate accounts $ - $ 2,206,608 $ - $ 2,206,608 Total fair value liabilities $ - $ 2,206,608 $ - $ 2,206,608 December 31, 2021 Level 1 Level 2 Level 3 Total (In thousands) Fair value assets: Available-for-sale fixed-maturity securities: U.S. government and agencies $ - $ 32,400 $ - $ 32,400 Foreign government - 152,976 - 152,976 States and political subdivisions - 153,527 - 153,527 Corporates 5,898 1,707,786 - 1,713,684 Mortgage-and asset-backed securities: Residential mortgage-backed securities - 375,604 27 375,631 Commercial mortgage-backed securities - 145,525 - 145,525 Other asset-backed securities - 128,824 - 128,824 Total available-for-sale fixed-maturity securities 5,898 2,696,642 27 2,702,567 Short-term investments - 85,243 - 85,243 Total available-for-sale securities 5,898 2,781,885 27 2,787,810 Equity securities 37,912 1,070 3,569 42,551 Trading securities - 24,355 - 24,355 Cash and cash equivalents 351,508 40,993 - 392,501 Separate accounts - 2,799,992 - 2,799,992 Total fair value assets $ 395,318 $ 5,648,295 $ 3,596 $ 6,047,209 Fair value liabilities: Separate accounts $ - $ 2,799,992 $ - $ 2,799,992 Total fair value liabilities $ - $ 2,799,992 $ - $ 2,799,992 In estimating fair value of our investments, we use a third-party pricing service for approximately 99 % of our securities that are measured at fair value on a recurring basis. The remaining securities are primarily thinly-traded securities, such as private placements, and are valued using models based on observable inputs on public corporate spreads having similar characteristics (e.g., sector, average life and quality rating), liquidity and yield based on quality rating, average life and U.S. Treasury yields. All observable data inputs are corroborated by independent third-party data. We also corroborate pricing information provided by our third-party pricing service by performing a review of selected securities. Our review activities include: obtaining detailed information about the assumptions, inputs and methodologies used in pricing the security; documenting this information; and corroborating it by comparison to independently obtained prices and/or independently developed pricing methodologies. Furthermore, we perform internal reasonableness assessments on fair value determinations within our portfolio throughout the year and as of year-end, including pricing variance analyses and comparisons to alternative pricing sources and benchmark returns. If a fair value appears unusual relative to these assessments, we will re-examine the inputs and may challenge a fair value assessment made by the pricing service. If there is a known pricing error, we will request a reassessment by the pricing service. If the pricing service is unable to perform the reassessment on a timely basis, we will determine the appropriate price by requesting a reassessment from an alternative pricing service or other qualified source as necessary. We do not adjust quotes or prices except in a rare circumstance to resolve a known error. Because many fixed-maturity securities do not trade on a daily basis, third-party pricing services generally determine fair value using industry-standard methodologies, which vary by asset class. For corporates, governments, and agency securities, these methodologies include developing prices by incorporating available market information such as U.S. Treasury curves, benchmarking of similar securities including new issues, sector groupings, quotes from market participants and matrix pricing. Observable information is compiled and integrates relevant credit information, perceived market movements and sector news. Additionally, security prices are periodically back-tested to validate and/or refine models as conditions warrant. Market indicators and industry and economic events are also monitored as triggers to obtain additional data. For certain structured securities (such as mortgage- and asset-backed securities) with limited trading activity, third-party pricing services generally use industry-standard pricing methodologies that incorporate market information, such as index prices or discounting expected future cash flows based on underlying collateral, and quotes from market participants, to estimate fair value. If one or more of these input measures are not deemed observable for a particular security, the security will be classified as Level 3 in the fair value hierarchy. Where specific market information is unavailable for certain securities, pricing models produce estimates of fair value primarily using Level 2 inputs along with certain Level 3 inputs. These models include matrix pricing. The pricing matrix uses current U.S. Treasury rates and credit spreads received from third-party sources to estimate fair value. The credit spreads incorporate the issuer’s industry- or issuer-specific credit characteristics and the security’s time to maturity, if warranted. Remaining unpriced securities are valued using an estimate of fair value based on indicative market prices that include significant unobservable inputs not based on, nor corroborated by, market information, including the utilization of non-binding broker quotes. The roll-forward of the Level 3 assets measured at fair value on a recurring basis was as follows: Three months ended September 30, Nine months ended September 30, (1) 2022 2021 2022 2021 (In thousands) Level 3 assets, beginning of period $ 1,634 $ 3,336 $ 3,596 $ 2,047 Net unrealized gains (losses) included in other comprehensive income ( 8 ) 1 99 1 Realized gains (losses) and accretion (amortization) recognized in earnings ( 127 ) ( 125 ) ( 328 ) ( 359 ) Purchases 6,170 2,068 13,661 3,067 Sales - - - - Settlements 15 ( 1 ) ( 1,385 ) ( 2,191 ) Transfers into Level 3 - - 1,399 2,714 Transfers out of Level 3 - ( 1,501 ) ( 9,358 ) ( 1,501 ) Level 3 assets, end of period $ 7,684 $ 3,778 $ 7,684 $ 3,778 (1) Activities for investments that enter and exit Level 3 in different quarters within the same fiscal year are not eliminated until the full year amounts are presented. We obtain independent pricing quotes based on observable inputs as of the end of the reporting period for all securities in Level 2. Those inputs include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, market bids/offers, quoted prices for similar instruments in markets that are not active, and other relevant data. We monitor these inputs for market indicators, industry and economic events. There were no material transfers between Level 1 and Level 3 during the three and nine months ended September 30, 2022 and 2021. The carrying values and estimated fair values of our financial instruments were as follows: September 30, 2022 December 31, 2021 Carrying value Estimated fair value Carrying value Estimated fair value (In thousands) Assets: Fixed-maturity securities (available-for-sale) $ 2,457,989 $ 2,457,989 $ 2,702,567 $ 2,702,567 Fixed-maturity security (held-to-maturity) (3) 1,433,760 1,320,222 1,379,100 1,551,113 Short-term investments (available-for-sale) - - 85,243 85,243 Equity securities 33,079 33,079 42,551 42,551 Trading securities 3,718 3,718 24,355 24,355 Policy loans (3) 48,787 48,787 30,612 30,612 Deposit asset underlying 10 % coinsurance agreement (3) 226,902 226,902 231,368 231,368 Separate accounts 2,206,608 2,206,608 2,799,992 2,799,992 Liabilities: Notes payable - Long term (1) (2) $ 592,705 $ 471,511 $ 592,102 $ 605,667 Surplus note (1) (3) 1,433,293 1,316,919 1,378,585 1,545,854 Separate accounts 2,206,608 2,206,608 2,799,992 2,799,992 (1) Carrying value amounts shown are net of issuance costs . (2) Classified as a Level 2 fair value measurement. (3) Classified as a Level 3 fair value measurement. The fair values of financial instruments presented above are estimates of the fair values at a specific point in time using various sources and methods, including market quotations and a complex matrix system that takes into account issuer sector, quality, and spreads in the current marketplace. Financial Instruments Recognized at Fair Value in the Balance Sheet. Estimated fair values of investments in AFS securities are principally a function of current spreads and interest rates that are corroborated by independent third-party data. Therefore, the fair values presented are indicative of amounts we could realize or settle at the respective balance sheet date. We do not necessarily intend to dispose of or liquidate such instruments prior to maturity. Trading securities and equity securities, including common and nonredeemable preferred stocks, are carried at fair value. Segregated funds in separate accounts are carried at the underlying value of the variable insurance contracts, which is fair value. The carrying amounts for cash and cash equivalents, trade receivables, accrued investment income, accounts payable, notes payable – short term, cash collateral and payables for security transactions approximate their fair values due to the short-term nature of these instruments. Consequently, such financial instruments are not included in the above table.

Reinsurance

Reinsurance	9 Months Ended
	Sep. 30, 2022
Reinsurance Disclosures [Abstract]
Reinsurance	(5) Reinsurance We use reinsurance extensively, which has a significant effect on our results of operations. Reinsurance arrangements do not relieve us of our primary obligation to the policyholder. Details on in-force life insurance were as follows: September 30, 2022 December 31, 2021 (Dollars in thousands) Direct life insurance in-force $ 915,091,729 $ 905,819,671 Amounts ceded to other companies ( 782,367,621 ) ( 777,826,233 ) Net life insurance in-force $ 132,724,108 $ 127,993,438 Percentage of reinsured life insurance in-force 85 % 86 % Benefits and claims ceded to reinsurers during the three and nine months ended September 30, 2022 were $ 375.8 million and $ 1,218.8 million, respectively, compared to $ 486.7 million and $ 1,474.6 million, respectively, for the three and nine months ended September 30, 2021. Reinsurance recoverables as of September 30, 2022 and December 31, 2021 include ceded reserve balances, ceded claim liabilities, and ceded claims paid. Reinsurance recoverables and financial strength ratings by reinsurer were as follows: September 30, 2022 December 31, 2021 Reinsurance recoverables A.M. Best rating Reinsurance recoverables A.M. Best rating (In thousands) Swiss Re Life & Health America Inc. (Novated from Pecan Re, Inc.) (1) (2) $ 2,474,068 A+ $ - - Pecan Re Inc. (1)(2) - - 2,567,602 NR SCOR Global Life Reinsurance Companies (3) 385,653 A+ 426,634 A+ Munich Re of Malta (2) (5) 249,942 NR 278,591 NR Swiss Re Life & Health America Inc. (4) 238,280 A+ 259,239 A+ American Health and Life Insurance Company (2) 150,364 B++ 157,837 B++ Munich American Reassurance Company 134,059 A+ 142,705 A+ RGA Reinsurance 127,750 A+ 140,953 A+ Korean Reinsurance Company 119,526 A 134,048 A Hannover Life Reassurance Company 47,263 A+ 49,749 A+ TOA Reinsurance Company 36,590 A 38,909 A All other reinsurers 73,444 - 75,094 - Allowance for credit losses ( 3,042 ) ( 2,942 ) Reinsurance recoverables $ 4,033,897 $ 4,268,419 NR – not rated (1) Effective April 1, 2022, the coinsurance agreement with Pecan Re Inc. was novated and replaced by an agreement with Swiss Re Life and Health America, Inc. (2) Reinsurance recoverables includes balances ceded under coinsurance transactions of term life insurance policies that were in-force as of December 31, 2009. Amounts shown are net of their share of the reinsurance recoverables from other reinsurers. Arrangements with these reinsurers include collateral trust agreements held in support of reinsurance recoverables. (3) Includes amounts ceded to Transamerica Reinsurance Companies and fully retroceded to SCOR Global Life Reinsurance Companies. (4) Includes amounts ceded to Lincoln National Life Insurance and fully retroceded to Swiss Re Life & Health America Inc. (5) Entity is rated AA- by S&P. We estimate and recognize lifetime expected credit losses for reinsurance recoverables. In estimating the allowance for expected credit losses for reinsurance recoverables, we factor in the underlying collateral for reinsurance agreements where available. Specifically, for reinsurers with underlying trust assets, we compare the reinsurance recoverables balance to the underlying trust assets that mitigate the potential exposure to credit losses. We also analyze the financial condition of the reinsurers, as determined by third-party rating agencies, to determine the probability of default for the reinsurers. We then utilize a third-party credit default study to calculate an expected credit loss given default rate or recovery rate. The probability of default and loss given default rates are then applied to the reinsurers’ recoverable balance, while also factoring in any third-party letters of credit that support the reinsurance agreement, in order to calculate our current expected credit loss allowance. The rollforward of the allowance for credit losses on reinsurance recoverables were as follows: Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 (In thousands) Balance, beginning of period $ 2,964 $ 7,654 $ 2,942 $ 7,144 Current period provision for expected credit losses 78 - 270 510 Less: Collections from expected credit losses previously recorded - ( 53 ) ( 170 ) ( 53 ) Balance, at the end of period $ 3,042 $ 7,601 $ 3,042 $ 7,601

Policy Claims and Other Benefit

Policy Claims and Other Benefits Payable	9 Months Ended
	Sep. 30, 2022
Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense [Abstract]
Policy Claims and Other Benefits Payable	(6) Policy Claims and Other Benefits Payable Changes in policy claims incurred and other benefits payable were as follows: Nine months ended September 30, 2022 2021 (In thousands) Policy claims and other benefits payable, beginning of period $ 585,382 $ 519,711 Less reinsured policy claims and other benefits payable 638,007 545,857 Net balance, beginning of period ( 52,625 ) ( 26,146 ) Incurred related to current year 189,739 207,542 Incurred related to prior years (1) ( 3,383 ) ( 121 ) Total incurred 186,356 207,421 Claims paid related to current year, net of reinsured policy claims received ( 236,246 ) ( 276,730 ) Reinsured policy claims received related to prior years, net of claims paid 66,047 36,439 Total paid ( 170,199 ) ( 240,291 ) Foreign currency translation ( 659 ) 44 Net balance, end of period ( 37,127 ) ( 58,972 ) Add reinsured policy claims and other benefits payable 533,690 616,097 Balance, end of period $ 496,563 $ 557,125 (1) Includes the difference between our estimate of claims incurred but not yet reported as of period-end and the actual incurred claims reported after period-end. The liability for policy claims and other benefits payable on traditional life insurance products includes estimated unpaid claims that have been reported to us and claims incurred but not yet reported. We estimate claims incurred but not yet reported based on our historical claims activity, adjusted for any current new trends and conditions, and reported lag time experience.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2022
Stockholders Equity Note [Abstract]
Stockholders' Equity	(7) Stockholders’ Equity A reconciliation of the number of shares of our outstanding common stock follows: Nine months ended September 30, 2022 2021 (In thousands) Common stock, beginning of period $ 39,368 $ 39,306 Shares issued for stock options exercised - 10 Shares of common stock issued upon lapse of sales restrictions on 201 204 Common stock retired ( 2,542 ) ( 49 ) Common stock, end of period $ 37,027 $ 39,471 The above reconciliation excludes RSUs and performance-based stock units (“PSUs”), which do not have voting rights. As sales restrictions on RSUs lapse and PSUs are earned, we issue common shares with voting rights. As of September 30, 2022, we had a total of 294,829 RSUs and 74,054 PSUs outstanding. The PSU outstanding balance is based on the number of PSUs granted pursuant to the award agreements; however, the actual number of common shares issued could be higher or lower based on actual versus targeted performance. See Note 9 (Share-Based Transactions) for discussion of the PSU award structure. On November 17, 2021 our Board of Directors authorized a share repurchase program for up to $ 275.0 million of our outstanding common stock for purchases through December 31, 2022 (the “Share Repurchase Program”). On February 14, 2022, our Board of Directors authorized an increase of $ 50.0 million to the Share Repurchase Program. On August 11, 2022, our Board of Directors authorized an additional increase of $ 50.0 million to the Share Repurchase Program bringing the authorized share repurchases to $ 375.0 million of our outstanding common stock through December 31, 2022. Under the Share Repurchase Program, we repurchased 2,628,425 shares of our common stock in the open market for an aggregate purchase price of $ 343.1 million through September 30, 2022. Approximately $ 31.9 million remains available for repurchases of our outstanding common stock under the Share Repurchase Program as of September 30, 2022 .

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Earnings Per Share	(8) Earnings Per Share The Company has outstanding common stock and equity awards that consist of RSUs, PSUs and stock options. The RSUs maintain non-forfeitable dividend rights that result in dividend payment obligations on a one-to-one ratio with common shares for any future dividend declarations. Unvested RSUs are deemed participating securities for purposes of calculating earnings per share (“EPS”) as they maintain dividend rights. We calculate EPS using the two-class method. Under the two-class method, we allocate earnings to common shares and vested RSUs outstanding for the period. Earnings attributable to unvested participating securities, along with the corresponding share counts, are excluded from EPS as reflected in our unaudited condensed consolidated statements of income. In calculating basic EPS, we deduct from net income any dividends and undistributed earnings allocated to unvested RSUs and then divide the result by the weighted-average number of common shares and vested RSUs outstanding for the period. We determine the potential dilutive effect of PSUs and stock options outstanding (“contingently-issuable shares”) on EPS using the treasury-stock method. Under this method, we determine the proceeds that would be received from the issuance of the contingently-issuable shares if the end of the reporting period were the end of the contingency period. The proceeds from the contingently-issuable shares include the remaining unrecognized compensation expense of the awards and the cash received for the exercise price on stock options. We then use the average market price of our common shares during the period the contingently-issuable shares were outstanding to determine how many shares we could repurchase with the proceeds raised from the issuance of the contingently-issuable shares. The net incremental share count issued represents the potential dilutive securities. We then reallocate earnings to common shares and vested RSUs by incorporating the increased fully-diluted share count to determine diluted EPS. The calculation of basic and diluted EPS was as follows: Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 (In thousands, except per-share amounts) Basic EPS: Numerator: Net income attributable to Primerica, Inc. $ 51,807 $ 112,456 $ 241,172 $ 338,489 Income attributable to unvested participating securities ( 244 ) ( 458 ) ( 1,067 ) ( 1,403 ) Net income used in calculating basic EPS $ 51,563 $ 111,998 $ 240,105 $ 337,086 Denominator: Weighted-average vested shares 37,438 39,561 38,342 39,516 Basic EPS $ 1.38 $ 2.83 $ 6.26 $ 8.53 Diluted EPS: Numerator: Net income attributable to Primerica, Inc. $ 51,807 $ 112,456 $ 241,172 $ 338,489 Income attributable to unvested participating securities ( 244 ) ( 457 ) ( 1,065 ) ( 1,399 ) Net income used in calculating diluted EPS $ 51,563 $ 111,999 $ 240,107 $ 337,090 Denominator: Weighted-average vested shares 37,438 39,561 38,342 39,516 Dilutive effect of incremental shares to be issued for 103 118 110 121 Weighted-average shares used in calculating diluted EPS 37,541 39,679 38,452 39,637 Diluted EPS $ 1.37 $ 2.82 $ 6.24 $ 8.50

Share-Based Transactions

Share-Based Transactions	9 Months Ended
	Sep. 30, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Transactions	(9) Share-Based Transactions The Company has outstanding equity awards under the Primerica, Inc. Second Amended and Restated 2010 Omnibus Incentive Plan (“2010 OIP”), which expired in 2020 in accordance with its terms and under which no future awards will be made, and the Primerica, Inc. 2020 Omnibus Incentive Plan (the “2020 OIP”, and together with the 2010 OIP, the “OIP”), which was approved by the Company’s stockholders on May 13, 2020. The OIP provides for the issuance of equity awards, including stock options, stock appreciation rights, restricted stock, deferred stock, RSUs, PSUs, and stock payment awards, as well as cash-based awards. In addition to time-based vesting requirements, awards granted under the OIP may also be subject to specified performance criteria. Under the OIP, the Company issues equity awards to our management (officers and other key employees), non-employees who serve on our Board of Directors, and sales force leaders. For more information on equity awards granted under the OIP, see Note 14 (Share-Based Transactions) to our consolidated financial statements within our 2021 Annual Report. In connection with our granting of equity awards to management and members of the Board of Directors, we recognize expense over the requisite service period of the equity award. We defer and amortize the fair value of equity awards granted to the sales force in the same manner as other deferred policy acquisition costs for those awards that are an incremental direct cost of successful acquisitions of life insurance policies that result directly from and are essential to the policy acquisition(s) and would not have been incurred had the policy acquisition(s) not occurred. All equity awards granted to the sales force that are not directly related to the successful acquisition of life insurance policies are recognized as expense as incurred, which is in the quarter granted and earned. The impact of equity awards granted under the OIP are as follows: Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 (In thousands) Equity awards expense recognized $ 1,060 $ 2,369 $ 16,068 $ 16,561 Equity awards expense deferred 2,691 2,048 7,878 7,227 On February 24, 2022, the Compensation Committee of our Board of Directors granted the following equity awards to employees as part of the annual approval of management incentive compensation: • 85,844 RSUs awarded to management with a measurement-date fair value of $ 130.3 0 per unit that have time-based vesting requirements with equal and annual graded vesting over approximately three years subsequent to the grant date. • 26,475 PSUs awarded to our four top executives with a measurement-date fair value of $ 130.3 0 per unit. The PSUs will be earned on March 1, 2025 contingent upon the Company achieving a targeted annual average three-year return on adjusted equity (“ROAE”) and average EPS growth for the period from January 1, 2022 through December 31, 2024. The actual number of common shares that will be issued will vary based on the actual ROAE and average EPS growth relative to the targeted ROAE and average EPS growth and can range from zero to 39,713 shares. All awards granted to employees on February 24, 2022 vest upon voluntary termination of employment by any employee who is “retirement eligible” as of his or her termination date. In order to be retirement eligible, an employee must be at least 55 years old and his or her age plus years of service with the Company must equal at least 75. The number of PSUs that will ultimately be issued for a retirement eligible employee is equal to the amount calculated using the Company’s actual cumulative three-year ROAE and average EPS growth for the performance period ending on December 31, 2024, even if that employee retires prior to the completion of the three-year performance period. During the three months ended September 30, 2022, 10,711 RSUs were awarded to certain members of management of e-TeleQuote with an average measurement-date fair value of $ 125.65 per unit that have time-based vesting requirements with equal and annual graded vesting over approximately three years subsequent to the grant date.

Commitments and Contingent Liab

Commitments and Contingent Liabilities	9 Months Ended
	Sep. 30, 2022
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingent Liabilities	(10) Commitments and Contingent Liabilities Letter of Credit (“LOC”). Peach Re maintains a credit facility agreement with Deutsche Bank (the “Credit Facility Agreement”) to support certain obligations for a portion of the Regulation XXX reserves related to the Peach Re Coinsurance Agreement. Under the Credit Facility Agreement, Deutsche Bank issued a letter of credit for the benefit of Primerica Life with a term expiring on December 31, 2025. As of September 30, 2022, the amount of the LOC outstanding was $ 102.8 million. This amount will decline over the remaining term of the LOC to correspond with declines in the Regulation XXX reserves. As of September 30, 2022, the Company was in compliance with all financial covenants under the Credit Facility Agreement. Further discussion on the Company’s letter of credit is included in Note 16 (Commitments and Contingent Liabilities) to our consolidated financial statements within our 2021 Annual Report. Contingent Liabilities. The Company is involved from time to time in legal disputes, regulatory inquiries and arbitration proceedings in the normal course of business. These disputes are subject to uncertainties, including the large and/or indeterminate amounts sought in certain of these matters and the inherent unpredictability of litigation. As such, the Company is unable to estimate the possible loss or range of loss that may result from these matters unless otherwise indicated.

Other Comprehensive Income

Other Comprehensive Income	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Other Comprehensive Income	(11) Other Comprehensive Income The components of other comprehensive income (“OCI”), including the income tax expense or benefit allocated to each component, were as follows: Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 (In thousands) Foreign currency translation adjustments: Change in unrealized foreign currency translation gains (losses) $ ( 18,086 ) $ ( 5,892 ) $ ( 24,048 ) $ 6,490 Income tax expense (benefit) on unrealized foreign currency - - - - Change in unrealized foreign currency translation gains $ ( 18,086 ) $ ( 5,892 ) $ ( 24,048 ) $ 6,490 Unrealized gain (losses) on available-for-sale securities: Change in unrealized holding gains (losses) arising during period $ ( 97,516 ) $ ( 13,796 ) $ ( 401,335 ) $ ( 52,669 ) Income tax expense (benefit) on unrealized holding gains ( 20,471 ) ( 2,991 ) ( 85,330 ) ( 11,653 ) Change in unrealized holding gains (losses) on available-for-sale ( 77,045 ) ( 10,805 ) ( 316,005 ) ( 41,016 ) Reclassification from accumulated OCI to net income for (gains) ( 154 ) ( 1,879 ) ( 867 ) ( 3,052 ) Income tax (expense) benefit on (gains) losses reclassified ( 33 ) ( 395 ) ( 182 ) ( 641 ) Reclassification from accumulated OCI to net income for (gains) ( 121 ) ( 1,484 ) ( 685 ) ( 2,411 ) Change in unrealized gains (losses) on available-for-sale $ ( 77,166 ) $ ( 12,289 ) $ ( 316,690 ) $ ( 43,427 )

Debt

Debt	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Debt	(12) Debt Notes Payable – Long Term. As of September 30, 2022, the Company had $ 600.0 million of publicly-traded, senior unsecured notes (the “Senior Notes”), with an annual interest rate of 2.80 % that are scheduled to mature on November 19, 2031 . As of September 30, 2022, we were in compliance with the covenants of the Senior Notes. No events of default occurred on the Senior Notes during the three and nine months ended September 30, 2022. Further discussion on the Company’s Senior Notes is included in Note 10 (Debt) to our consolidated financial statements within our 2021 Annual Report. Notes Payable – Short Term. On July 1, 2021, as part of the acquisition of e-TeleQuote, Primerica Health issued a $ 15.0 million unsecured, subordinated note, guaranteed by the Parent Company, to Etelequote Limited’s (“Etelequote Bermuda”) majority shareholder (the “Majority Shareholder Note”). This note was retired during the nine months ended September 30, 2022. Surplus Note. As of September 30, 2022, the principal amount outstanding on the Surplus Note issued by Vidalia Re was $ 1.4 billion, which is equal to the principal amount of the LLC Note. The principal amount of both the Surplus Note and the LLC Note will fluctuate over time to coincide with the amount of policy reserves being contractually supported under the Vidalia Re Coinsurance Agreement. Both the LLC Note and the Surplus Note mature on December 31, 2030 and bear interest at an annual interest rate of 4.50 % . Based on the estimated reserves for policies issued in 2011 through 2017 that have been ceded under the Vidalia Re Coinsurance Agreement, the principal amounts of the Surplus Note and the LLC Note are expected to reach $ 1.5 billion each. This financing arrangement is non-recourse to the Parent Company and Primerica Life, meaning that neither of these companies has guaranteed the Surplus Note or is otherwise liable for reimbursement for any payments triggered by the LLC Note’s credit enhancement feature. The Parent Company has agreed to support Vidalia Re’s obligation to pay the credit enhancement fee incurred on the LLC Note. Further discussion on the Company’s LLC Note is included in Note 3 (Investments). Revolving Credit Facility. We maintain an unsecured $ 200.0 million revolving credit facility (“Revolving Credit Facility”) with a syndicate of commercial banks. The Revolving Credit Facility has a scheduled termination date of June 22, 2026 . Amounts outstanding under the Revolving Credit Facility are borrowed, at our discretion, on the basis of either a LIBOR rate loan, or a base rate loan. LIBOR rate loans bear interest at a periodic rate equal to one-, three-, six-, or 12-month LIBOR, plus an applicable margin. Base rate loans bear interest at the highest of (a) the Prime Rate, (b) the Federal Funds Rate plus 0.50% and (c) one-month LIBOR plus 1.00%, plus an applicable margin. The Revolving Credit Facility contains language providing for a benchmark replacement in the event that LIBOR is no longer available. The Revolving Credit Facility also permits the issuance of letters of credit. The applicable margins are based on our debt rating with such margins for LIBOR rate loans and letters of credit ranging from 1.00 % to 1.625 % per annum and for base rate loans ranging from 0.00 % to 0.625 % per annum. Under the Revolving Credit Facility, we incur a commitment fee that is payable quarterly in arrears and is determined by our debt rating. This commitment fee ranges from 0.10 % to 0.225 % per annum of the aggregate amount of the $ 200.0 million commitment of the lenders under the Revolving Credit Facility that remains undrawn. During the three and nine months ended September 30, 2022 , no amounts have been drawn under the Revolving Credit Facility and we were in compliance with the covenants. Furthermore, no events of default occurred under the Revolving Credit Facility during the three and nine months ended September 30, 2022 .

Revenue from Contracts with Cus

Revenue from Contracts with Customers	9 Months Ended
	Sep. 30, 2022
Revenue From Contract With Customer [Abstract]
Revenue from Contract with Customers	(13) Revenue from Contracts with Customers Our revenues from contracts with customers primarily include: • Commissions and fees earned for the marketing and distribution of investment and savings products underwritten by mutual fund companies and annuity providers. For purposes of revenue recognition, mutual fund companies and annuity providers are considered the customers in marketing and distribution arrangements; • Fees earned for investment advisory and administrative services within our managed investments program and shareholder services fees earned in Canada for mutual funds for which we serve as principal distributor; • Account-based fees for transfer agent recordkeeping functions and non-bank custodial services; • Commissions and fees earned from the distribution of Medicare-related insurance products on behalf of health insurance carriers, including tail revenue adjustments; • Marketing development revenues earned for selling Medicare-related insurance products on behalf of health insurance carriers, which is recorded in Other, net revenue; • Fees associated with mortgage distribution and the distribution of other third-party financial products; and • Other revenue from the sale of miscellaneous products and services including monthly subscription fees from the sales representatives for access to Primerica Online (“POL”), our primary sales force support tool. Premiums from insurance contracts we underwrite, fees received from segregated funds insurance contracts, and income earned on our invested assets are excluded from the definition of revenues from contracts with customers in accordance with U.S. GAAP. Further discussion on the Company’s revenues from contracts with customers and revenue recognition policies are included in Note 18 (Revenue from Contracts with Customers) to our consolidated financial statements within our 2021 Annual Report. The disaggregation of our revenues from contracts with customers were as follows: Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 (In thousands) Term Life Insurance segment revenues: Other, net $ 13,419 $ 12,476 $ 37,969 $ 36,601 Total segment revenues from contracts with customers 13,419 12,476 37,969 36,601 Revenues from sources other than contracts with customers 414,411 388,975 1,218,998 1,130,415 Total Term Life Insurance segment revenues $ 427,830 $ 401,451 $ 1,256,967 $ 1,167,016 Investment and Savings Products segment revenues: Commissions and fees Sales-based revenues $ 67,962 $ 95,229 $ 259,905 $ 298,057 Asset-based revenues 93,068 97,184 283,841 275,084 Account-based revenues 22,910 21,456 67,043 64,424 Other, net 3,342 3,094 9,508 9,001 Total segment revenues from contracts with customers 187,282 216,963 620,297 646,566 Revenues from sources other than contracts 14,415 16,374 44,855 48,204 Total Investment and Savings Products segment revenues $ 201,697 $ 233,337 $ 665,152 $ 694,770 Senior Health segment revenues: Commissions and fees $ 14,601 $ 21,558 $ 25,222 $ 21,558 Other, net 2,583 1,378 9,606 1,378 Total Senior Health segment revenues $ 17,184 $ 22,936 $ 34,828 $ 22,936 Corporate and Other Distributed Products segment revenues: Commissions and fees $ 12,512 $ 17,995 $ 37,090 $ 47,202 Other, net 1,621 1,103 3,626 2,978 Total segment revenues from contracts with customers 14,133 19,098 40,716 50,180 Revenues from sources other than contracts with customers 12,445 16,417 35,531 50,736 Total Corporate and Other Distributed Products segment revenues $ 26,578 $ 35,515 $ 76,247 $ 100,916 Renewal Commissions Receivable. For revenue associated with ongoing renewal commissions in the Senior Health and Corporate and Other Distributed Products segments, we record a renewal commission receivable asset for the amount of ongoing renewal commissions we anticipate collecting in reporting periods subsequent to the satisfaction of the performance obligation, less amounts that are constrained in the accompanying unaudited condensed consolidated balance sheets. We update our estimate of variable consideration each period and new facts or circumstances that were not available at the time of the initial estimate will indicate that the expected renewal commissions are higher or lower than our renewal commissions receivable. As such, the expected renewal commissions receivable will be written down or up to its revised expected value by adjustments to revenue, which we refer to as tail revenue adjustments. During the three months ended September 30, 2022, we recognized a positive tail revenue adjustment due to renewal rate escalations communicated by health insurance carriers during the quarter. During the nine months ended September 30, 2022, we recognized a net negative tail revenue adjustment to reduce the balance of the renewal commissions receivable in the Senior Health business as retention for policies scheduled to renew during the period was lower than expectations. Activity in the Renewal commissions receivable account was as follows: Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 (In thousands) Senior Health segment: Balance, beginning of period $ 134,212 $ - $ 172,308 $ - Contract balances acquired as part of business combination - 199,575 - 199,575 Measurement period adjustment (1) - - ( 11,863 ) - Commissions revenue 9,600 16,526 32,011 16,526 Less: collections ( 8,808 ) ( 6,842 ) ( 33,032 ) ( 6,842 ) Tail revenue adjustments from change in estimate 1,700 - ( 22,720 ) - Balance, at the end of period $ 136,704 $ 209,259 $ 136,704 $ 209,259 Corporate and Other Distributed Products segments: Balance, beginning of period $ 59,449 $ 56,683 $ 59,443 $ 54,845 Commissions revenue 7,908 8,810 19,833 21,969 Less: collections ( 6,034 ) ( 5,800 ) ( 17,953 ) ( 17,121 ) Balance, at the end of period $ 61,323 $ 59,693 $ 61,323 $ 59,693 (1) The measurement period adjustment was recorded during the nine months ended September 30, 2022 in order to finalize the purchase price allocation for the acquisition of e-TeleQuote. Refer to Note 14 (Acquisition) for further details. Incremental costs to obtain or fulfill contracts, most notably sales commissions to the sales representatives, are not incurred prior to the recognition of the related revenue. Therefore, we have no assets recognized for incremental costs to obtain or fulfill contracts.

Acquisition

Acquisition	9 Months Ended
	Sep. 30, 2022
Business Combinations [Abstract]
Acquisition	(14) Acquisition On July 1, 2021 (the "Acquisition Date"), the Company acquired an 80 % interest, as described in the next paragraph, in the operating subsidiaries of Etelequote Bermuda, including e-TeleQuote, a Florida corporation that is a senior health insurance distributor of Medicare-related insurance policies in all 50 states and Puerto Rico (the “Acquisition”). The Company’s subsidiary, Primerica Health, purchased from the shareholders of Etelequote Bermuda (the “selling shareholders”) 100 % of the issued and outstanding capital stock of e-TeleQuote and its subsidiaries for consideration of (i) approximately $ 350 million in cash, (ii) replacement of e-TeleQuote’s debt as of the closing date of $ 146 million with intercompany funding provided by the Parent Company, (iii) a $ 15 million Majority Shareholder Note and (iv) common shares of Primerica Health constituting 20 % of the total issued and outstanding shares of capital stock of Primerica Health that were issued to Etelequote Bermuda’s minority shareholders, most of which included or were beneficially owned by e-TeleQuote’s management (“Noncontrolling Equity Holders”). The cash consideration provided was subsequently reduced by $ 3.9 million as a result of the final purchase price agreed upon with the sellers following finalization of the closing statement. In connection with the Company’s acquisition of e-TeleQuote, the Company entered into a shareholders’ agreement with the noncontrolling equity holders of Primerica Health (the “Shareholders’ Agreement”) which, among other matters, sets forth certain call and put rights beginning in 2022. Under the terms of the Shareholders’ Agreement, the Company agreed to purchase, and the noncontrolling equity holders agreed to sell, the remaining 20 % stake over a period of up to four years through a series of call and put rights. The Shareholders’ Agreement provides for the purchase of the noncontrolling equity holders’ equity interests in Primerica Health at a contractually defined formulaic purchase price (the “Formulaic Price”), which is based on a discounted calculation of selected peer company equity value multiples times the trailing twelve months of adjusted earnings before interest, taxes, depreciation, and amortization (“Adjusted EBITDA”) reduced by the balance of intercompany debt owed by e-TeleQuote to the Parent Company. Effective July 1, 2022 , the Company executed its call option to acquire the remaining 20 % of Primerica Health. The Formulaic Price calculation resulted in a purchase price of zero . As such, no further consideration was required to obtain the outstanding 20% stake in Primerica Health and the noncontrolling interest in the Company's consolidated financial statements was redeemed. The following table presents the preliminary purchase price allocation recorded in the Company’s consolidated balance sheet as of the Acquisition Date, adjustments made during the measurement period that ended June 30, 2022, and the final purchase price allocation: Preliminary Purchase Price Adjustment 2021 Measurement Period Adjustments 2022 Measurement Period Adjustments Final Acquisition Date Purchase Price Allocation (In thousands) Assets: Cash and cash equivalent 1,080 - - 1,080 Accounts receivables 692 ( 389 ) - 303 Renewal commissions receivable 199,575 ( 46,128 ) ( 11,863 ) 141,584 Other assets 15,705 - - 15,705 Intangible assets 162,000 ( 6,000 ) - 156,000 Goodwill 224,180 30,973 8,553 263,706 Total assets 603,232 ( 21,544 ) ( 3,310 ) 578,378 Liabilities: Accounts payable and accrued expenses 8,785 ( 4,195 ) (1) - 4,590 Deferred tax liability 65,425 ( 13,482 ) ( 3,310 ) 48,633 Other liabilities 10,046 - - 10,046 Total liabilities 84,256 ( 17,677 ) ( 3,310 ) 63,269 Net assets acquired 518,976 ( 3,867 ) - 515,109 Temporary Stockholders' Equity: Redeemable noncontrolling interests 8,437 - - 8,437 Total temporary stockholders' equity 8,437 8,437 (1) The Company also recognized an adjustment during the measurement period to reclassify certain amounts from a payable to a reduction in the renewal commissions receivable. Renewal commissions receivable from the acquired business was recognized in accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC 606” ) as the Company adopted Accounting Standards Update No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). ASU 2021-08 requires contract assets arising from revenue contracts with customers to be accounted for in accordance with ASC 606 instead of at fair value. During the measurement period, the Company made two adjustments to renewal commissions receivable as of the Acquisition Date. The adjustments, which were booked in 2021 and 2022 resulted from the Company’s reassessment of the estimates made by e-TeleQuote for the variable consideration expected for approved policies as of the Acquisition Date. The reassessment of estimates involved the implementation of an enhanced algorithmic model for processing historical lapse data and forecasting future policy duration curves. In addition, the Company revised the estimate for renewal commission rate escalation assumptions in accordance with its accounting policy for determining constraints of variable consideration. As a result, the Company recognized a purchase price allocation adjustment to decrease renewal commissions receivable and deferred tax liability with a corresponding increase to goodwill. Intangible assets identified in the acquisition of the business are capitalized separately from goodwill if the fair value can be measured reliably on initial recognition (transaction date). The primary intangible assets identified were customer relationships with health insurance carriers of $ 153.0 million with an estimated useful life of 15 years. The Company will amortize the intangible assets acquired on a straight-line basis over their estimated useful lives. During the measurement period, the Company revised long-term growth rates used in the cash flow projections that support the intangibles valuation. As a result, the Company recognized a purchase price allocation adjustment to decrease intangible assets and deferred tax liability with a corresponding increase to goodwill. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration transferred and the aggregate values assigned to the assets acquired and liabilities assumed. The amount of goodwill calculated as of the Acquisition Date determined by the final purchase price allocation was $ 263.7 million. The goodwill created in the acquisition is not deductible for tax purposes. Refer to Note 15 (Goodwill) for more information regarding the valuation of goodwill.

Goodwill

Goodwill	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	(15) Goodwill Goodwill represents the excess of the purchase price over the estimated acquired values of identifiable assets and liabilities acquired in a business combination at the acquisition date. In accordance with U.S. GAAP, goodwill is not amortized. The Company tests goodwill for impairment annually on July 1 and whenever events occur or circumstances change that would indicate the carrying value of goodwill may be impaired. All of the Company’s goodwill was obtained from the Acquisition and the e-TeleQuote business has been designated as a separate operating segment called Senior Health. Therefore, goodwill has been allocated solely to the Senior Health segment and is evaluated for impairment at the Senior Health segment level, which is also defined as the reporting unit. During the annual impairment test as of July 1, 2022, the Company performed a quantitative impairment analysis using the income approach by preparing a discounted cash flow analysis to determine the reporting unit’s fair value. The discounted cash flow analysis included key assumptions such as the weighted average cost of capital ("WACC'), long-term growth rate and projected operating results such as approved policies, lifetime value of commissions, contract acquisition costs, operating expenses, collections of renewal commissions receivable, and utilization of net operating losses for income tax purposes. We did not utilize a market approach as part of the quantitative impairment analysis as we believe management’s expectations of the cash flow generated by the reporting unit were more relevant in determining fair value given inherent limitations in the credibility of available peer company data. The measurement of the reporting unit’s fair value is classified as a Level 3 fair value measurement given the significance of the unobservable inputs such as forecasted operating results and discount rates. After the fair value of the reporting unit was determined, the Company calculated its carrying value by taking the reporting unit’s assets minus its liabilities. The carrying value of the reporting unit was then compared to its fair value to determine the extent of any goodwill impairment. Based on this analysis, we recognized a non-cash goodwill impairment charge of $ 60.0 million during the three months ended September 30, 2022, which represents the excess of the Senior Health reporting unit’s carrying value over its estimated fair value at July 1, 2022. The goodwill impairment charge recognized did not impact the Company’s income tax expense as the goodwill acquired from the Acquisition does not have any tax basis. The decline in the reporting unit's fair value below its carrying value was primarily attributable to an increase in the market-based WACC used to discount the forecasted cash flows. The increase in the WACC was driven by recent increases in the equity market risk premium and higher interest rates. The determination of whether the carrying value of the reporting unit exceeds its fair value involves a high degree of estimation and can be affected by a number of industry and company-specific risk factors that are subject to change over time. At September 30, 2022, the Company recognized goodwill of $ 127.7 million in its Senior Health reporting unit after accumulated goodwill impairment charges since the Acquisition Date of $ 136.0 million.

Description of Business, Basi_2

Description of Business, Basis of Presentation, and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation . We prepare our financial statements in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). These principles are established primarily by the Financial Accounting Standards Board (“FASB”). The accompanying unaudited condensed consolidated financial statements contain all adjustments, generally consisting of normal recurring accruals, which are necessary to fairly present the balance sheets as of September 30, 2022 and December 31, 2021, the statements of income, comprehensive income, and stockholders’ equity for the three and nine months ended September 30, 2022 and 2021, and cash flows for the nine months ended September 30, 2022 and 2021. Results of operations for interim periods are not necessarily indicative of results for the entire year or of the results to be expected in future periods. These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are sufficient to make the information not misleading. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto that are included in our Annual Report on Form 10-K for the year ended December 31, 2021 (“2021 Annual Report”).
Use of Estimates	Use of Estimates. The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect financial statement balances, revenues and expenses and cash flows, as well as the disclosure of contingent assets and liabilities. Management considers available facts and knowledge of existing circumstances when establishing the estimates included in our financial statements. The most significant items that involve a greater degree of accounting estimates and actuarial determinations subject to change in the future are the valuation of investments, deferred policy acquisition costs (“DAC”), future policy benefit reserves and corresponding amounts recoverable from reinsurers, renewal commissions receivable, income taxes, and valuation of intangible assets and goodwill. Estimates for these and other items are subject to change and are reassessed by management in accordance with U.S. GAAP. Actual results could differ from those estimates.
Consolidation	Consolidation. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and those entities required to be consolidated under U.S. GAAP. All material intercompany profits, transactions, and balances among the consolidated entities have been eliminated.
Reclassifications	Reclassifications. Certain reclassifications have been made to prior-period amounts to conform to current-period reporting classifications. These reclassifications had no impact on net income or total stockholders’ equity.
Changes to Accounting Policies	Changes to Accounting Policies . All significant accounting policies remain unchanged from the 2021 Annual Report unless otherwise described.
New Accounting Principles	Future Application of Accounting Standards. In August 2018, the FASB issued Accounting Standards Update No. 2018-12 , Financial Services—Insurance (Topic 944) — Targeted Improvements to the Accounting for Long-Duration Contracts (“ASU 2018-12” or “LDTI”). The amendments in this update change accounting guidance for insurance companies that issue long-duration contracts, including term life insurance . ASU 2018-12 requires companies that issue long-duration insurance contracts to update assumptions used in measuring future policy benefits and DAC, including mortality, disability, and persistency, at least annually instead of locking those assumptions at contract inception and reflecting differences in assumptions and actual performance as the experience occurs. ASU 2018-12 also changes how insurance companies that issue long-duration contracts amortize DAC and determine and update the discount rate assumptions used in measuring future policy benefits reserves while increasing the level of financial statement disclosures required. The guidance in ASU 2018-12 will be applied to the earliest period presented in the consolidated financial statements beginning on the effective date of January 1, 2023. The adoption of ASU 2018-12 will have an impact on our consolidated financial statements and related disclosures and will require changes to certain of our processes, systems, and controls. We are continuing to evaluate the impact the adoption will have on our consolidated financial statements. We are working on model refinement and model governance, finalizing actuarial assumptions and documenting our control process. Below is a list of topics relevant to the adoption of ASU 2018-12 and the expected impact on the Company. Topic Description Planned Approach Transition Approach LDTI guidance can be applied using either: • the retrospective method, which applies the provisions of the standard from the original policy inception; or • the modified retrospective method, which applies the provisions of the standard by pivoting off the historical December 31, 2020 future policy benefits reserve (“Pre-transition Reserve”) and deferred acquisition costs (“DAC”) balances just prior to January 1, 2021 (the “Transition Date”). The Company will elect to adopt the standard using the modified retrospective method for both future policy benefits reserves and amortization of DAC. The Company will adopt the standard effective January 1, 2023. Cohort Definition Cohorts refer to the level of policy grouping used in the calculation of the future policy benefits reserve (“FPBR”) and amortization of DAC. Under LDTI, cohorts must vary by policy issue year and may be set more granularly to reflect additional policy characteristics. The net premium ratio for each policy cohort is used to calculate FPBR. At the Transition Date, the Net Premium Ratio is defined as the present value of future benefits and claim settlement expenses less the Pre-transition Reserve divided by the present value of the gross premiums. The present value of both the future benefits and gross premiums use best estimate cash flow assumptions at the locked-in discount rate (discount rate at the Transition Date). Under LDTI, a cohort’s Net Premium Ratio is capped at 100 %. This concept replaces the need for loss recognition analysis under current GAAP. Any adjustments necessary at the Transition Date to cap the Net Premium Ratio for a cohort at 100 % are recognized in retained earnings. After the Transition Date, the Net Premium Ratio will be updated each quarter as projected benefits and premiums are replaced with actual amounts. The Company will define its Term Life Insurance segment cohorts based on the legal entity that issued the policy and the year the policy was issued. The Company expects the impact as of the Transition Date of capping the Net Premium Ratio at 100 % to be less than 3 % of total retained earnings. The identified impact from capping the Net Premium Ratio at 100 % is primarily attributable to a limited amount of older policy year cohorts. Discount Rates LDTI requires entities to use market observable rates, based on an upper-medium grade fixed income instrument yield, to measure future policy benefits reserves each period. The difference between the FPBR calculated using market observable rates and the Pre-transition Reserve is recognized as part of accumulated other comprehensive income (“AOCI”) at the Transition Date. After the Transition Date, the impact of changes in market observable rates each quarter will be recorded to AOCI and may add volatility to our reported equity. The Company will use discount rates applied by geography to align with local currency cash flows. Discount rates will consist of yield curves that will be developed using Bloomberg’s Evaluated Pricing Product (BVAL) based on senior unsecured fixed rate bonds ratings of A+, A or A-. Given how low market observable rates were at the Transition Date, we expect that the amount recorded in AOCI as of the Transition Date will reduce our AOCI and equity balances by approximately $ 1.2 to $ 1.5 billion, net of income tax. As of September 30, 2022, market observable rates have increased relative to the Transition Date, which will significantly reduce the AOCI impact in equity on our current balance sheet. If we were to apply market observable rates as of September 30, 2022 to the FPBR as of the Transition Date, the impact on AOCI would be between a $ 150 million increase and a $ 150 million decrease on an after-tax basis. Cash Flow Assumptions LDTI requires entities to use their best estimates for cash flow assumptions with no provision for adverse deviation. Cash flow assumptions are to be reviewed at least annually at the same time each year, or more frequently if experience suggests. Forecasted cash flow assumptions must be replaced with actual cash flows in FPBR at least annually. The Company expects to formally review cash flow assumptions during the third quarter each year and update these assumptions as necessary. The Company will replace forecasted cash flow assumptions with actual cash flows in FPBR each quarter. The impact of assumption changes and experience variances will be partly reflected in the current period and partly spread to future periods, based on the remaining duration of the impacted cohort(s), by unlocking the Net Premium Ratio in FPBR. DAC Amortization LDTI requires DAC to be amortized on a constant-level basis over the expected term of the contracts using an appropriate unit of measure. Companies can amortize DAC either at an individual contract level on a straight-line basis or at a cohort level that approximates a straight-line basis. Under current GAAP, DAC is amortized using amortization models linked to revenue or profit. Also, interest is accrued on unamortized DAC under current GAAP while LDTI disallows the accrual of interest. The Company anticipates it will use current face amount as a unit of measure to amortize DAC for its term life insurance products and policy count as a unit of measure to amortize DAC for its Canadian segregated funds products. In addition, the Company expects to group contracts by cohort to amortize DAC. For term life insurance products, we expect DAC to be amortized more slowly under LDTI as compared with current GAAP. For Canadian segregated funds, we expect DAC amortization to be less volatile than under current GAAP as it will no longer be based on the present value of gross profits, which are subject to changes in the market value of assets under management. Market Risk Benefits (“MRBs”) MRBs are benefits that protect policyholders from capital market risk. Under LDTI, MRBs are measured at fair value. The Company has MRBs from limited guaranteed benefits provided as part of our Canadian segregated funds products. We are still undergoing the process of evaluating MRBs associated with our Canadian segregated funds products but we currently anticipate that the fair value of MRBs associated with this product will be immaterial when LDTI is adopted. Recently-issued accounting guidance not discussed above is not applicable, is not material to our unaudited condensed consolidated financial statements, or did not or is not expected to have a material impact on our business.

Segment and Geographical Info_2

Segment and Geographical Information (Tables)	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Summary of Assets and Profit or Loss by Segment	Notable information included in profit or loss by segment was as follows: Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 (In thousands) Revenues: Term life insurance segment $ 427,830 $ 401,451 $ 1,256,967 $ 1,167,016 Investment and savings products segment 201,697 233,337 665,152 694,770 Senior health segment 17,184 22,936 34,828 22,936 Corporate and other distributed products segment 26,578 35,515 76,247 100,916 Total revenues $ 673,289 $ 693,239 $ 2,033,194 $ 1,985,638 Net investment income: Term life insurance segment $ 13,241 $ 9,320 $ 36,973 $ 26,324 Investment and savings products segment - - - - Senior health segment - - - - Corporate and other distributed products segment 11,105 10,680 27,562 34,264 Total net investment income $ 24,346 $ 20,000 $ 64,535 $ 60,588 Amortization of DAC: Term life insurance segment $ 88,275 $ 59,287 $ 249,826 $ 174,106 Investment and savings products segment 2,222 2,580 11,610 7,641 Senior health segment - - - - Corporate and other distributed products segment 428 347 931 857 Total amortization of DAC $ 90,925 $ 62,214 $ 262,367 $ 182,604 Non-cash share-based compensation expense: Term life insurance segment $ 645 $ 570 $ 3,388 $ 3,303 Investment and savings products segment 672 665 2,559 2,532 Senior health segment 67 - 67 - Corporate and other distributed products segment ( 324 ) ( 594 ) 13,638 8,999 Total non-cash share-based compensation expense $ 1,060 $ 641 $ 19,652 $ 14,834 Income (loss) before income taxes: Term life insurance segment $ 111,764 $ 107,589 $ 323,220 $ 312,603 Investment and savings products segment 58,377 69,368 181,913 203,885 Senior health segment ( 63,723 ) ( 8,490 ) ( 102,959 ) ( 8,490 ) Corporate and other distributed products segment ( 20,519 ) ( 21,365 ) ( 75,971 ) ( 63,123 ) Total income (loss) before income taxes $ 85,899 $ 147,102 $ 326,203 $ 444,875
Total Assets by Segment	Total assets by segment were as follows: September 30, 2022 December 31, 2021 (In thousands) Assets: Term life insurance segment $ 7,164,005 $ 7,274,820 Investment and savings products segment (1) 2,324,810 2,920,271 Senior health segment 428,317 528,974 Corporate and other distributed products segment 5,125,011 5,399,158 Total assets $ 15,042,143 $ 16,123,223 (1) The Investment and Savings Products segment includes assets held in separate accounts. Excluding separate accounts, the Investment and Savings Products segment assets were $ 118.2 million and $ 120.3 million as of September 30, 2022 and December 31, 2021 , respectively.
Long Lived Assets and Continuing Operations by Country	Geographical Information. Results of operations by country and long-lived assets, primarily tangible assets reported in other assets in our unaudited condensed consolidated balance sheets and condensed consolidated statements of income, were as follows: Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 (In thousands) Revenues by country: United States $ 588,954 $ 594,406 $ 1,750,621 $ 1,687,868 Canada 84,335 98,833 282,573 297,770 Total revenues $ 673,289 $ 693,239 $ 2,033,194 $ 1,985,638 September 30, 2022 December 31, 2021 (In thousands) Long-lived assets by country: United States $ 51,147 $ 62,921 Canada 3,111 3,871 Other 233 230 Total long-lived assets $ 54,491 $ 67,022

Investments (Tables)

Investments (Tables)	9 Months Ended
	Sep. 30, 2022
Investments Debt And Equity Securities [Abstract]
Schedule of Available-for-sale Securities	The period-end amortized cost, gross unrealized gains and losses, and fair value of available-for-sale securities were as follows: September 30, 2022 Amortized cost Gross unrealized gains Gross unrealized losses Fair value (In thousands) Securities available-for-sale, carried at fair value: Fixed-maturity securities: U.S. government and agencies $ 32,698 $ 20 $ ( 980 ) $ 31,738 Foreign government 150,507 474 ( 11,037 ) 139,944 States and political subdivisions 142,852 59 ( 21,789 ) 121,122 Corporates 1,668,098 1,985 ( 194,251 ) 1,475,832 Residential mortgage-backed securities 477,103 251 ( 65,328 ) 412,026 Commercial mortgage-backed securities 139,940 3 ( 14,204 ) 125,739 Other asset-backed securities 167,817 - ( 16,229 ) 151,588 Total fixed-maturity securities 2,779,015 2,792 ( 323,818 ) 2,457,989 December 31, 2021 Amortized cost Gross unrealized gains Gross unrealized losses Fair value (In thousands) Securities available-for-sale, carried at fair value: Fixed-maturity securities: U.S. government and agencies $ 32,292 $ 187 $ ( 79 ) $ 32,400 Foreign government 147,288 6,283 ( 595 ) 152,976 States and political subdivisions 147,455 6,326 ( 254 ) 153,527 Corporates 1,649,334 72,418 ( 8,068 ) 1,713,684 Residential mortgage-backed securities 373,753 5,108 ( 3,230 ) 375,631 Commercial mortgage-backed securities 142,631 3,314 ( 420 ) 145,525 Other asset-backed securities 128,635 1,409 ( 1,220 ) 128,824 Total fixed-maturity securities 2,621,388 95,045 ( 13,866 ) 2,702,567 Short-term investments 85,246 1 ( 4 ) 85,243 Total fixed-maturity and short-term investments $ 2,706,634 $ 95,046 $ ( 13,870 ) $ 2,787,810
Fixed-maturity Securities Classified by Contractual Maturity Date	The scheduled maturity distribution of the available-for-sale fixed-maturity portfolio as of September 30, 2022 was as follows: Amortized cost Fair value (In thousands) Due in one year or less $ 185,346 $ 184,509 Due after one year through five years 768,889 724,190 Due after five years through 10 years 747,297 627,289 Due after 10 years 292,623 232,648 1,994,155 1,768,636 Mortgage- and asset-backed securities 784,860 689,353 Total AFS fixed-maturity securities $ 2,779,015 $ 2,457,989
Costs and Fair Value of Securities Classified as Trading Securities	The cost and fair value of the securities classified as trading securities were as follows: September 30, 2022 December 31, 2021 Cost Fair value Cost Fair value (In thousands) Fixed-maturity securities $ 4,335 $ 3,718 $ 24,769 $ 24,355
Net Investment Income	Investment Income. The components of net investment income were as follows: Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 (In thousands) Fixed-maturity securities (available-for-sale) $ 23,067 $ 19,860 $ 66,370 $ 60,035 Fixed-maturity security (held-to-maturity) 16,283 15,741 47,613 46,382 Equity securities 373 413 1,131 1,216 Policy loans and other invested assets 436 289 596 618 Cash and cash equivalents 1,714 96 2,338 371 Total return on deposit asset underlying 10% coinsurance agreement (1) 489 346 ( 1,790 ) 1,989 Gross investment income 42,362 36,745 116,258 110,611 Investment expenses ( 1,733 ) ( 1,004 ) ( 4,110 ) ( 3,641 ) Investment income net of investment expenses 40,629 35,741 112,148 106,970 Interest expense on surplus note ( 16,283 ) ( 15,741 ) ( 47,613 ) ( 46,382 ) Net investment income $ 24,346 $ 20,000 $ 64,535 $ 60,588 (1) For the three months ended September 30, 2022, includes less than ($ 0.1 ) million of net losses recognized for the change in fair value of the deposit asset underlying the 10 % coinsurance agreement. For the nine months ended September 30, 2022, includes $( 3.4 ) million of net losses recognized for the change in fair value of the deposit asset underlying the 10 % coinsurance agreement. For the three and nine months ended September 30, 2021, includes $( 0.6 ) million and $( 1.6 ) million, respectively, of net losses recognized for the change in fair value of the deposit asset underlying the 10 % coinsurance agreement.
Schedule of Components of Investment Gains (Losses)	The components of investment gains (losses), as well as details on gross realized investment gains (losses) and other investment gains (losses) were as follows: Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 (In thousands) Realized investment gains (losses): Gross gains from sales of available-for-sale securities fixed maturity securities $ 491 $ 1,801 $ 1,512 $ 5,780 Gross losses from sales of available-for-sale fixed maturity securities ( 199 ) ( 71 ) ( 588 ) ( 2,018 ) Net realized investment gains (losses): 292 1,730 924 3,762 Other investment gains (losses): Credit losses impairment of available-for-sale securities ( 138 ) 149 ( 57 ) ( 710 ) Market gains (losses) recognized in net income during the period on equity securities ( 2,858 ) ( 418 ) ( 4,692 ) 1,117 Gains (losses) from bifurcated options - 1 - ( 48 ) Gains (losses) on trading securities 5 ( 52 ) ( 16 ) ( 245 ) Other investment gains (losses): ( 2,991 ) ( 320 ) ( 4,765 ) 114 Investment gains (losses) $ ( 2,699 ) $ 1,410 $ ( 3,841 ) $ 3,876
Schedule of Proceeds from Sales or Other Redemptions of Available-for-Sale Securities	The proceeds from sales or other redemptions of available-for-sale securities were as follows: Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 (In thousands) Proceeds from sales or other redemptions $ 117,909 $ 135,393 $ 419,985 $ 449,564
Schedule of Securities in Unrealized Loss Position	The following table summarizes all available-for-sale securities in an unrealized loss position for which an allowance for credit losses has not been recorded as of September 30, 2022, aggregated by major security type and length of time such securities have continuously been in an unrealized loss position: September 30, 2022 Less than 12 months 12 months or longer Fair value Unrealized losses Fair value Unrealized losses (Dollars in thousands) Fixed-maturity securities: U.S. government and agencies $ 27,735 $ ( 744 ) $ 2,170 $ ( 236 ) Foreign government 114,843 ( 7,332 ) 17,132 ( 3,705 ) States and political subdivisions 105,750 ( 18,900 ) 11,798 ( 2,889 ) Corporates 1,202,033 ( 127,943 ) 239,948 ( 66,308 ) Residential mortgage-backed securities 301,304 ( 41,127 ) 103,895 ( 24,201 ) Commercial mortgage-backed securities 96,986 ( 10,949 ) 28,352 ( 3,255 ) Other asset-backed securities 102,080 ( 8,368 ) 49,508 ( 7,861 ) Total fixed-maturity securities 1,950,731 ( 215,363 ) 452,803 ( 108,455 ) December 31, 2021 Less than 12 months 12 months or longer Fair value Unrealized losses Fair value Unrealized losses (Dollars in thousands) Fixed-maturity securities: U.S. government and agencies $ 24,928 $ ( 45 ) $ 1,557 $ ( 34 ) Foreign government 18,894 ( 384 ) 3,335 ( 211 ) States and political subdivisions 15,909 ( 254 ) - - Corporates 341,963 ( 5,035 ) 59,414 ( 3,033 ) Residential mortgage-backed securities 234,911 ( 3,131 ) 2,707 ( 99 ) Commercial mortgage-backed securities 47,220 ( 419 ) 117 ( 1 ) Other asset-backed securities 80,509 ( 1,037 ) 3,779 ( 183 ) Total fixed-maturity securities 764,334 ( 10,305 ) 70,909 ( 3,561 ) Short-term investments: U.S. government and agencies 34,967 * - - Foreign government 4,995 * - - States and political subdivisions 11,394 ( 1 ) - - Corporates 23,891 ( 3 ) - - Total short-term investments 75,247 ( 4 ) - - Total fixed-maturity securities and short-term investments $ 839,581 $ ( 10,309 ) $ 70,909 $ ( 3,561 ) * Less than $ 1 thousand.
Schedule of Securities in Allowance for Credit Losses	The rollforward of the allowance for credit losses on available-for-sale securities were as follows: Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 (In thousands) Allowance for credit losses, beginning of period $ - $ 858 $ 816 $ - Additions to the allowance for credit losses on securities for which credit losses were not previously recorded - 6 - 160 Additional increases or (decreases) to the allowance for credit losses on securities that had an allowance recorded in a previous period - ( 154 ) ( 81 ) 550 Write-offs charged against the allowance, if any - - ( 735 ) - Allowance for credit losses, end of period $ - $ 710 $ - $ 710

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis	The estimated fair value and hierarchy classifications for assets and liabilities that are measured at fair value on a recurring basis were as follows: September 30, 2022 Level 1 Level 2 Level 3 Total (In thousands) Fair value assets: Available-for-sale fixed-maturity securities: U.S. government and agencies $ - $ 31,738 $ - $ 31,738 Foreign government - 139,944 - 139,944 States and political subdivisions - 121,122 - 121,122 Corporates 3,811 1,472,021 - 1,475,832 Mortgage- and asset-backed securities: Residential mortgage-backed securities - 408,228 3,798 412,026 Commercial mortgage-backed securities - 124,741 998 125,739 Other asset-backed securities - 150,214 1,374 151,588 Total available-for-sale fixed-maturity securities 3,811 2,448,008 6,170 2,457,989 Short-term investments - - - - Total available-for-sale securities 3,811 2,448,008 6,170 2,457,989 Equity securities 30,577 988 1,514 33,079 Trading securities - 3,718 - 3,718 Cash and cash equivalents 438,025 - - 438,025 Separate accounts - 2,206,608 - 2,206,608 Total fair value assets $ 472,413 $ 4,659,322 $ 7,684 $ 5,139,419 Fair value liabilities: Separate accounts $ - $ 2,206,608 $ - $ 2,206,608 Total fair value liabilities $ - $ 2,206,608 $ - $ 2,206,608 December 31, 2021 Level 1 Level 2 Level 3 Total (In thousands) Fair value assets: Available-for-sale fixed-maturity securities: U.S. government and agencies $ - $ 32,400 $ - $ 32,400 Foreign government - 152,976 - 152,976 States and political subdivisions - 153,527 - 153,527 Corporates 5,898 1,707,786 - 1,713,684 Mortgage-and asset-backed securities: Residential mortgage-backed securities - 375,604 27 375,631 Commercial mortgage-backed securities - 145,525 - 145,525 Other asset-backed securities - 128,824 - 128,824 Total available-for-sale fixed-maturity securities 5,898 2,696,642 27 2,702,567 Short-term investments - 85,243 - 85,243 Total available-for-sale securities 5,898 2,781,885 27 2,787,810 Equity securities 37,912 1,070 3,569 42,551 Trading securities - 24,355 - 24,355 Cash and cash equivalents 351,508 40,993 - 392,501 Separate accounts - 2,799,992 - 2,799,992 Total fair value assets $ 395,318 $ 5,648,295 $ 3,596 $ 6,047,209 Fair value liabilities: Separate accounts $ - $ 2,799,992 $ - $ 2,799,992 Total fair value liabilities $ - $ 2,799,992 $ - $ 2,799,992
Roll forward of Level 3 Assets Measured on Recurring Basis	The roll-forward of the Level 3 assets measured at fair value on a recurring basis was as follows: Three months ended September 30, Nine months ended September 30, (1) 2022 2021 2022 2021 (In thousands) Level 3 assets, beginning of period $ 1,634 $ 3,336 $ 3,596 $ 2,047 Net unrealized gains (losses) included in other comprehensive income ( 8 ) 1 99 1 Realized gains (losses) and accretion (amortization) recognized in earnings ( 127 ) ( 125 ) ( 328 ) ( 359 ) Purchases 6,170 2,068 13,661 3,067 Sales - - - - Settlements 15 ( 1 ) ( 1,385 ) ( 2,191 ) Transfers into Level 3 - - 1,399 2,714 Transfers out of Level 3 - ( 1,501 ) ( 9,358 ) ( 1,501 ) Level 3 assets, end of period $ 7,684 $ 3,778 $ 7,684 $ 3,778 (1) Activities for investments that enter and exit Level 3 in different quarters within the same fiscal year are not eliminated until the full year amounts are presented.
Carrying Values and Estimated Fair Values of Financial Instruments	The carrying values and estimated fair values of our financial instruments were as follows: September 30, 2022 December 31, 2021 Carrying value Estimated fair value Carrying value Estimated fair value (In thousands) Assets: Fixed-maturity securities (available-for-sale) $ 2,457,989 $ 2,457,989 $ 2,702,567 $ 2,702,567 Fixed-maturity security (held-to-maturity) (3) 1,433,760 1,320,222 1,379,100 1,551,113 Short-term investments (available-for-sale) - - 85,243 85,243 Equity securities 33,079 33,079 42,551 42,551 Trading securities 3,718 3,718 24,355 24,355 Policy loans (3) 48,787 48,787 30,612 30,612 Deposit asset underlying 10 % coinsurance agreement (3) 226,902 226,902 231,368 231,368 Separate accounts 2,206,608 2,206,608 2,799,992 2,799,992 Liabilities: Notes payable - Long term (1) (2) $ 592,705 $ 471,511 $ 592,102 $ 605,667 Surplus note (1) (3) 1,433,293 1,316,919 1,378,585 1,545,854 Separate accounts 2,206,608 2,206,608 2,799,992 2,799,992 (1) Carrying value amounts shown are net of issuance costs . (2) Classified as a Level 2 fair value measurement. (3) Classified as a Level 3 fair value measurement.

Reinsurance (Tables)

Reinsurance (Tables)	9 Months Ended
	Sep. 30, 2022
Reinsurance Disclosures [Abstract]
In-force Life Insurance	Details on in-force life insurance were as follows: September 30, 2022 December 31, 2021 (Dollars in thousands) Direct life insurance in-force $ 915,091,729 $ 905,819,671 Amounts ceded to other companies ( 782,367,621 ) ( 777,826,233 ) Net life insurance in-force $ 132,724,108 $ 127,993,438 Percentage of reinsured life insurance in-force 85 % 86 %
Reinsurance Recoverable and Financial Strength Ratings by Reinsurer	Reinsurance recoverables as of September 30, 2022 and December 31, 2021 include ceded reserve balances, ceded claim liabilities, and ceded claims paid. Reinsurance recoverables and financial strength ratings by reinsurer were as follows: September 30, 2022 December 31, 2021 Reinsurance recoverables A.M. Best rating Reinsurance recoverables A.M. Best rating (In thousands) Swiss Re Life & Health America Inc. (Novated from Pecan Re, Inc.) (1) (2) $ 2,474,068 A+ $ - - Pecan Re Inc. (1)(2) - - 2,567,602 NR SCOR Global Life Reinsurance Companies (3) 385,653 A+ 426,634 A+ Munich Re of Malta (2) (5) 249,942 NR 278,591 NR Swiss Re Life & Health America Inc. (4) 238,280 A+ 259,239 A+ American Health and Life Insurance Company (2) 150,364 B++ 157,837 B++ Munich American Reassurance Company 134,059 A+ 142,705 A+ RGA Reinsurance 127,750 A+ 140,953 A+ Korean Reinsurance Company 119,526 A 134,048 A Hannover Life Reassurance Company 47,263 A+ 49,749 A+ TOA Reinsurance Company 36,590 A 38,909 A All other reinsurers 73,444 - 75,094 - Allowance for credit losses ( 3,042 ) ( 2,942 ) Reinsurance recoverables $ 4,033,897 $ 4,268,419 NR – not rated (1) Effective April 1, 2022, the coinsurance agreement with Pecan Re Inc. was novated and replaced by an agreement with Swiss Re Life and Health America, Inc. (2) Reinsurance recoverables includes balances ceded under coinsurance transactions of term life insurance policies that were in-force as of December 31, 2009. Amounts shown are net of their share of the reinsurance recoverables from other reinsurers. Arrangements with these reinsurers include collateral trust agreements held in support of reinsurance recoverables. (3) Includes amounts ceded to Transamerica Reinsurance Companies and fully retroceded to SCOR Global Life Reinsurance Companies. (4) Includes amounts ceded to Lincoln National Life Insurance and fully retroceded to Swiss Re Life & Health America Inc. (5) Entity is rated AA- by S&P.
Allowance for Credit Loss on Reinsurance Recoverable	The rollforward of the allowance for credit losses on reinsurance recoverables were as follows: Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 (In thousands) Balance, beginning of period $ 2,964 $ 7,654 $ 2,942 $ 7,144 Current period provision for expected credit losses 78 - 270 510 Less: Collections from expected credit losses previously recorded - ( 53 ) ( 170 ) ( 53 ) Balance, at the end of period $ 3,042 $ 7,601 $ 3,042 $ 7,601

Policy Claims and Other Benef_2

Policy Claims and Other Benefits Payable (Tables)	9 Months Ended
	Sep. 30, 2022
Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense [Abstract]
Schedule of Liability For Future Policy Benefits and Unpaid Claims	Changes in policy claims incurred and other benefits payable were as follows: Nine months ended September 30, 2022 2021 (In thousands) Policy claims and other benefits payable, beginning of period $ 585,382 $ 519,711 Less reinsured policy claims and other benefits payable 638,007 545,857 Net balance, beginning of period ( 52,625 ) ( 26,146 ) Incurred related to current year 189,739 207,542 Incurred related to prior years (1) ( 3,383 ) ( 121 ) Total incurred 186,356 207,421 Claims paid related to current year, net of reinsured policy claims received ( 236,246 ) ( 276,730 ) Reinsured policy claims received related to prior years, net of claims paid 66,047 36,439 Total paid ( 170,199 ) ( 240,291 ) Foreign currency translation ( 659 ) 44 Net balance, end of period ( 37,127 ) ( 58,972 ) Add reinsured policy claims and other benefits payable 533,690 616,097 Balance, end of period $ 496,563 $ 557,125 (1) Includes the difference between our estimate of claims incurred but not yet reported as of period-end and the actual incurred claims reported after period-end.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2022
Stockholders Equity Note [Abstract]
Reconciliation of Number of Shares of Common Stock	A reconciliation of the number of shares of our outstanding common stock follows: Nine months ended September 30, 2022 2021 (In thousands) Common stock, beginning of period $ 39,368 $ 39,306 Shares issued for stock options exercised - 10 Shares of common stock issued upon lapse of sales restrictions on 201 204 Common stock retired ( 2,542 ) ( 49 ) Common stock, end of period $ 37,027 $ 39,471

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Calculation of Basic and Diluted Earnings Per Share	The calculation of basic and diluted EPS was as follows: Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 (In thousands, except per-share amounts) Basic EPS: Numerator: Net income attributable to Primerica, Inc. $ 51,807 $ 112,456 $ 241,172 $ 338,489 Income attributable to unvested participating securities ( 244 ) ( 458 ) ( 1,067 ) ( 1,403 ) Net income used in calculating basic EPS $ 51,563 $ 111,998 $ 240,105 $ 337,086 Denominator: Weighted-average vested shares 37,438 39,561 38,342 39,516 Basic EPS $ 1.38 $ 2.83 $ 6.26 $ 8.53 Diluted EPS: Numerator: Net income attributable to Primerica, Inc. $ 51,807 $ 112,456 $ 241,172 $ 338,489 Income attributable to unvested participating securities ( 244 ) ( 457 ) ( 1,065 ) ( 1,399 ) Net income used in calculating diluted EPS $ 51,563 $ 111,999 $ 240,107 $ 337,090 Denominator: Weighted-average vested shares 37,438 39,561 38,342 39,516 Dilutive effect of incremental shares to be issued for 103 118 110 121 Weighted-average shares used in calculating diluted EPS 37,541 39,679 38,452 39,637 Diluted EPS $ 1.37 $ 2.82 $ 6.24 $ 8.50

Share-Based Transactions (Table

Share-Based Transactions (Tables)	9 Months Ended
	Sep. 30, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Impact of Equity Awards Granted	The impact of equity awards granted under the OIP are as follows: Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 (In thousands) Equity awards expense recognized $ 1,060 $ 2,369 $ 16,068 $ 16,561 Equity awards expense deferred 2,691 2,048 7,878 7,227

Other Comprehensive Income (Tab

Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The components of other comprehensive income (“OCI”), including the income tax expense or benefit allocated to each component, were as follows: Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 (In thousands) Foreign currency translation adjustments: Change in unrealized foreign currency translation gains (losses) $ ( 18,086 ) $ ( 5,892 ) $ ( 24,048 ) $ 6,490 Income tax expense (benefit) on unrealized foreign currency - - - - Change in unrealized foreign currency translation gains $ ( 18,086 ) $ ( 5,892 ) $ ( 24,048 ) $ 6,490 Unrealized gain (losses) on available-for-sale securities: Change in unrealized holding gains (losses) arising during period $ ( 97,516 ) $ ( 13,796 ) $ ( 401,335 ) $ ( 52,669 ) Income tax expense (benefit) on unrealized holding gains ( 20,471 ) ( 2,991 ) ( 85,330 ) ( 11,653 ) Change in unrealized holding gains (losses) on available-for-sale ( 77,045 ) ( 10,805 ) ( 316,005 ) ( 41,016 ) Reclassification from accumulated OCI to net income for (gains) ( 154 ) ( 1,879 ) ( 867 ) ( 3,052 ) Income tax (expense) benefit on (gains) losses reclassified ( 33 ) ( 395 ) ( 182 ) ( 641 ) Reclassification from accumulated OCI to net income for (gains) ( 121 ) ( 1,484 ) ( 685 ) ( 2,411 ) Change in unrealized gains (losses) on available-for-sale $ ( 77,166 ) $ ( 12,289 ) $ ( 316,690 ) $ ( 43,427 )

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	9 Months Ended
	Sep. 30, 2022
Revenue From Contract With Customer [Abstract]
Summary of Disaggregation of Revenues from Contracts	The disaggregation of our revenues from contracts with customers were as follows: Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 (In thousands) Term Life Insurance segment revenues: Other, net $ 13,419 $ 12,476 $ 37,969 $ 36,601 Total segment revenues from contracts with customers 13,419 12,476 37,969 36,601 Revenues from sources other than contracts with customers 414,411 388,975 1,218,998 1,130,415 Total Term Life Insurance segment revenues $ 427,830 $ 401,451 $ 1,256,967 $ 1,167,016 Investment and Savings Products segment revenues: Commissions and fees Sales-based revenues $ 67,962 $ 95,229 $ 259,905 $ 298,057 Asset-based revenues 93,068 97,184 283,841 275,084 Account-based revenues 22,910 21,456 67,043 64,424 Other, net 3,342 3,094 9,508 9,001 Total segment revenues from contracts with customers 187,282 216,963 620,297 646,566 Revenues from sources other than contracts 14,415 16,374 44,855 48,204 Total Investment and Savings Products segment revenues $ 201,697 $ 233,337 $ 665,152 $ 694,770 Senior Health segment revenues: Commissions and fees $ 14,601 $ 21,558 $ 25,222 $ 21,558 Other, net 2,583 1,378 9,606 1,378 Total Senior Health segment revenues $ 17,184 $ 22,936 $ 34,828 $ 22,936 Corporate and Other Distributed Products segment revenues: Commissions and fees $ 12,512 $ 17,995 $ 37,090 $ 47,202 Other, net 1,621 1,103 3,626 2,978 Total segment revenues from contracts with customers 14,133 19,098 40,716 50,180 Revenues from sources other than contracts with customers 12,445 16,417 35,531 50,736 Total Corporate and Other Distributed Products segment revenues $ 26,578 $ 35,515 $ 76,247 $ 100,916
Summary of Renewal Commissions Receivable	Activity in the Renewal commissions receivable account was as follows: Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 (In thousands) Senior Health segment: Balance, beginning of period $ 134,212 $ - $ 172,308 $ - Contract balances acquired as part of business combination - 199,575 - 199,575 Measurement period adjustment (1) - - ( 11,863 ) - Commissions revenue 9,600 16,526 32,011 16,526 Less: collections ( 8,808 ) ( 6,842 ) ( 33,032 ) ( 6,842 ) Tail revenue adjustments from change in estimate 1,700 - ( 22,720 ) - Balance, at the end of period $ 136,704 $ 209,259 $ 136,704 $ 209,259 Corporate and Other Distributed Products segments: Balance, beginning of period $ 59,449 $ 56,683 $ 59,443 $ 54,845 Commissions revenue 7,908 8,810 19,833 21,969 Less: collections ( 6,034 ) ( 5,800 ) ( 17,953 ) ( 17,121 ) Balance, at the end of period $ 61,323 $ 59,693 $ 61,323 $ 59,693 (1) The measurement period adjustment was recorded during the nine months ended September 30, 2022 in order to finalize the purchase price allocation for the acquisition of e-TeleQuote. Refer to Note 14 (Acquisition) for further details.

Acquisition (Tables)

Acquisition (Tables)	9 Months Ended
	Sep. 30, 2022
Business Combinations [Abstract]
Summary of Identified Assets Acquired and Liabilities Assumed at Acquisition Date	The following table presents the preliminary purchase price allocation recorded in the Company’s consolidated balance sheet as of the Acquisition Date, adjustments made during the measurement period that ended June 30, 2022, and the final purchase price allocation: Preliminary Purchase Price Adjustment 2021 Measurement Period Adjustments 2022 Measurement Period Adjustments Final Acquisition Date Purchase Price Allocation (In thousands) Assets: Cash and cash equivalent 1,080 - - 1,080 Accounts receivables 692 ( 389 ) - 303 Renewal commissions receivable 199,575 ( 46,128 ) ( 11,863 ) 141,584 Other assets 15,705 - - 15,705 Intangible assets 162,000 ( 6,000 ) - 156,000 Goodwill 224,180 30,973 8,553 263,706 Total assets 603,232 ( 21,544 ) ( 3,310 ) 578,378 Liabilities: Accounts payable and accrued expenses 8,785 ( 4,195 ) (1) - 4,590 Deferred tax liability 65,425 ( 13,482 ) ( 3,310 ) 48,633 Other liabilities 10,046 - - 10,046 Total liabilities 84,256 ( 17,677 ) ( 3,310 ) 63,269 Net assets acquired 518,976 ( 3,867 ) - 515,109 Temporary Stockholders' Equity: Redeemable noncontrolling interests 8,437 - - 8,437 Total temporary stockholders' equity 8,437 8,437 (1) The Company also recognized an adjustment during the measurement period to reclassify certain amounts from a payable to a reduction in the renewal commissions receivable.

Description of Business, Basi_3

Description of Business, Basis of Presentation, and Summary of Significant Accounting Policies - Narrative (Details) - USD ($) $ in Millions			9 Months Ended
	Jul. 01, 2022	Jul. 01, 2021	Sep. 30, 2022
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]
Future policy benefits reserve percentage of net premium ratio			100%
Percentage of net premium ratio capped			100%
Accounting standards update [extensible enumeration]			us-gaap:AccountingStandardsUpdate201812Member
Increase in AOCI upon application of market observable rates			$ 150
Decrease in AOCI upon application of market observable rates			$ 150
Term Life Insurance Segment [Member]
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]
Percentage of net premium ratio capped			100%
Accounting standards update [extensible enumeration]			us-gaap:AccountingStandardsUpdate201812Member
Maximum [Member]
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]
Future policy benefits reserve percentage of retained earnings			3%
AOCI and equity, net of income tax			$ 1,500
Minimum [Member]
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]
AOCI and equity, net of income tax			$ 1,200
Etelequote Bermuda [Member]
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]
Business acquisition, date of acquisition agreement		Jul. 01, 2021
Percentage of interest acquired		80%
Remaining percentage of interest acquired	20%
Business acquisition, effective date of acquisition	Jul. 01, 2022

Segment and Geographical Info_3

Segment and Geographical Information - Narrative (Details)	9 Months Ended
	Sep. 30, 2022 Segment
Segment Reporting [Abstract]
Number of operating segments	3

Segment and Geographical Info_4

Segment and Geographical Information - Summary of Assets and Profit or Loss by Segment (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Segment Reporting Information [Line Items]
Revenues		$ 673,289	$ 693,239	$ 2,033,194	$ 1,985,638
Net investment income		24,346	20,000	64,535	60,588
Amortization of deferred policy acquisition costs		90,925	62,214	262,367	182,604
Non-cash share-based compensation expense		1,060	641	19,652	14,834
Income (loss) before income taxes		85,899	147,102	326,203	444,875
Assets		15,042,143		15,042,143		$ 16,123,223
Term Life Insurance Segment [Member]
Segment Reporting Information [Line Items]
Revenues		427,830	401,451	1,256,967	1,167,016
Net investment income		13,241	9,320	36,973	26,324
Amortization of deferred policy acquisition costs		88,275	59,287	249,826	174,106
Non-cash share-based compensation expense		645	570	3,388	3,303
Income (loss) before income taxes		111,764	107,589	323,220	312,603
Assets		7,164,005		7,164,005		7,274,820
Investment and Savings Products Segment [Member]
Segment Reporting Information [Line Items]
Revenues		201,697	233,337	665,152	694,770
Amortization of deferred policy acquisition costs		2,222	2,580	11,610	7,641
Non-cash share-based compensation expense		672	665	2,559	2,532
Income (loss) before income taxes		58,377	69,368	181,913	203,885
Assets	[1]	2,324,810		2,324,810		2,920,271
Senior Health Segment [Member]
Segment Reporting Information [Line Items]
Revenues		17,184	22,936	34,828	22,936
Non-cash share-based compensation expense		67		67
Income (loss) before income taxes		(63,723)	(8,490)	(102,959)	(8,490)
Assets		428,317		428,317		528,974
Corporate and Other Distributed Products Segment [Member]
Segment Reporting Information [Line Items]
Revenues		26,578	35,515	76,247	100,916
Net investment income		11,105	10,680	27,562	34,264
Amortization of deferred policy acquisition costs		428	347	931	857
Non-cash share-based compensation expense		(324)	(594)	13,638	8,999
Income (loss) before income taxes		(20,519)	$ (21,365)	(75,971)	$ (63,123)
Assets		$ 5,125,011		$ 5,125,011		$ 5,399,158
[1] The Investment and Savings Products segment includes assets held in separate accounts. Excluding separate accounts, the Investment and Savings Products segment assets were $ 118.2 million and $ 120.3 million as of September 30, 2022 and December 31, 2021 , respectively.

Segment and Geographical Info_5

Segment and Geographical Information - Summary of Assets and Profit or Loss by Segment (Parenthetical) (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Investment and Savings Products Segment [Member]
Segment Reporting Information [Line Items]
Assets, excluding separate account assets	$ 118.2	$ 120.3

Segment and Geographical Info_6

Segment and Geographical Information - Long Lived Assets and Continuing Operations by Country (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues	$ 673,289	$ 693,239	$ 2,033,194	$ 1,985,638
Long-lived assets	54,491		54,491		$ 67,022
United States [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues	588,954	594,406	1,750,621	1,687,868
Long-lived assets	51,147		51,147		62,921
Canada [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues	84,335	$ 98,833	282,573	$ 297,770
Long-lived assets	3,111		3,111		3,871
Other [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Long-lived assets	$ 233		$ 233		$ 230

Investments - Schedule of Avail

Investments - Schedule of Available-for-sale Securities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale debt securities, at fair value	$ 2,457,989	$ 2,702,567
U.S. Government and Agencies [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale debt securities, amortized cost basis	32,698	32,292
Available-for-sale debt securities gross unrealized gain	20	187
Available-for-sale debt securities, gross unrealized loss	(980)	(79)
Available-for-sale debt securities, at fair value	31,738	32,400
Foreign Government [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale debt securities, amortized cost basis	150,507	147,288
Available-for-sale debt securities gross unrealized gain	474	6,283
Available-for-sale debt securities, gross unrealized loss	(11,037)	(595)
Available-for-sale debt securities, at fair value	139,944	152,976
States and Political Subdivisions [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale debt securities, amortized cost basis	142,852	147,455
Available-for-sale debt securities gross unrealized gain	59	6,326
Available-for-sale debt securities, gross unrealized loss	(21,789)	(254)
Available-for-sale debt securities, at fair value	121,122	153,527
Corporates [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale debt securities, amortized cost basis	1,668,098	1,649,334
Available-for-sale debt securities gross unrealized gain	1,985	72,418
Available-for-sale debt securities, gross unrealized loss	(194,251)	(8,068)
Available-for-sale debt securities, at fair value	1,475,832	1,713,684
Residential Mortgage-backed Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale debt securities, amortized cost basis	477,103	373,753
Available-for-sale debt securities gross unrealized gain	251	5,108
Available-for-sale debt securities, gross unrealized loss	(65,328)	(3,230)
Available-for-sale debt securities, at fair value	412,026	375,631
Commercial Mortgage-backed Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale debt securities, amortized cost basis	139,940	142,631
Available-for-sale debt securities gross unrealized gain	3	3,314
Available-for-sale debt securities, gross unrealized loss	(14,204)	(420)
Available-for-sale debt securities, at fair value	125,739	145,525
Other Asset-backed Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale debt securities, amortized cost basis	167,817	128,635
Available-for-sale debt securities gross unrealized gain		1,409
Available-for-sale debt securities, gross unrealized loss	(16,229)	(1,220)
Available-for-sale debt securities, at fair value	151,588	128,824
Fixed-Maturity Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale debt securities, amortized cost basis	2,779,015	2,621,388
Available-for-sale debt securities gross unrealized gain	2,792	95,045
Available-for-sale debt securities, gross unrealized loss	(323,818)	(13,866)
Available-for-sale debt securities, at fair value	2,457,989	2,702,567
Short-Term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale debt securities, amortized cost basis	$ 0	85,246
Available-for-sale debt securities gross unrealized gain		1
Available-for-sale debt securities, gross unrealized loss		(4)
Available-for-sale debt securities, at fair value		85,243
Fixed-Maturity Securities and Short-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale debt securities, amortized cost basis		2,706,634
Available-for-sale debt securities gross unrealized gain		95,046
Available-for-sale debt securities, gross unrealized loss		(13,870)
Available-for-sale debt securities, at fair value		$ 2,787,810

Investments - Fixed-maturity Se

Investments - Fixed-maturity Securities Classified by Contractual Maturity Date (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Available-for-sale Securities, Debt Maturities [Abstract]
Available-for-sale debt securities, at fair value	$ 2,457,989	$ 2,702,567
Fixed Maturities
Available-for-sale Securities, Debt Maturities [Abstract]
Due in one year or less, amortized cost	185,346
Due after one year through five years, amortized cost	768,889
Due after five years through 10 years, amortized cost	747,297
Due after 10 years, amortized cost	292,623
Total fixed-maturity securities with single maturity dates, amortized cost	1,994,155
Mortgage and asset-backed securities, amortized cost	784,860
Available-for-sale debt securities, amortized cost basis	2,779,015	2,621,388
Due in one year or less, fair value	184,509
Due after one year through five years, fair value	724,190
Due after five years through 10 years, fair value	627,289
Due after 10 years, fair value	232,648
Total fixed-maturity securities with single maturity dates, fair value	1,768,636
Mortgage and asset-backed securities, fair value	689,353
Available-for-sale debt securities, at fair value	$ 2,457,989	$ 2,702,567

Investments - Costs and Fair Va

Investments - Costs and Fair Value of Securities Classified as Trading Securities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Total trading securities, cost	$ 4,335	$ 24,769
Fixed Maturities
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Total trading securities, cost	4,335	24,769
Total trading securities, Fair value	$ 3,718	$ 24,355

Investments - Held-to-maturity

Investments - Held-to-maturity Security - Narrative (Details)	9 Months Ended
	Sep. 30, 2022 USD ($)
Schedule Of Held To Maturity Securities [Line Items]
Held-to-maturity debt security estimated unrealized holding loss	$ 113,500,000
Held-to-maturity debt security Credit losses	$ 0
LLC Note [Member]
Schedule Of Held To Maturity Securities [Line Items]
Debt instrument, maturity date	Dec. 31, 2030
Debt instrument, interest rate, stated percentage	4.50%
Surplus Note [Member]
Schedule Of Held To Maturity Securities [Line Items]
Debt instrument, maturity date	Dec. 31, 2030
Debt instrument, interest rate, stated percentage	4.50%

Investments - Fair Value of Inv

Investments - Fair Value of Investments on Deposit with Governmental Authorities - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Investments Debt And Equity Securities [Abstract]
Fair values of investments on deposit	$ 7.1	$ 7.6

Investments - Securities Lendin

Investments - Securities Lending Collateral - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Securities Received as Collateral [Abstract]
Securities loaned, minimum collateral to loan ratio	102%
Securities loaned, additional collateral requirement, decline in collateral value threshold percentage	100%
Cash collateral received and reinvested	$ 80.8	$ 94.5

Investments - Net Investment In

Investments - Net Investment Income (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Schedule of Net Investment Income, Reported Amounts, by Category [Line Items]
Gross investment income, operating		$ 42,362	$ 36,745	$ 116,258	$ 110,611
Investment expenses		(1,733)	(1,004)	(4,110)	(3,641)
Investment income net of investment expenses		40,629	35,741	112,148	106,970
Interest expense on surplus note		(16,283)	(15,741)	(47,613)	(46,382)
Net investment income		24,346	20,000	64,535	60,588
Equity Securities [Member]
Schedule of Net Investment Income, Reported Amounts, by Category [Line Items]
Gross investment income, operating		373	413	1,131	1,216
Policy Loans and Other Invested Assets [Member]
Schedule of Net Investment Income, Reported Amounts, by Category [Line Items]
Gross investment income, operating		436	289	596	618
Cash and Cash Equivalents [Member]
Schedule of Net Investment Income, Reported Amounts, by Category [Line Items]
Gross investment income, operating		1,714	96	2,338	371
Total return on deposit asset underlying 10% insurance agreement [Member]
Schedule of Net Investment Income, Reported Amounts, by Category [Line Items]
Gross investment income, operating	[1]	489	346	(1,790)	1,989
Available-for-Sale [Member] | Fixed Maturities
Schedule of Net Investment Income, Reported Amounts, by Category [Line Items]
Gross investment income, operating		23,067	19,860	66,370	60,035
Held-to-Maturity [Member] | Fixed Maturities
Schedule of Net Investment Income, Reported Amounts, by Category [Line Items]
Gross investment income, operating		$ 16,283	$ 15,741	$ 47,613	$ 46,382
[1] For the three months ended September 30, 2022, includes less than ($ 0.1 ) million of net losses recognized for the change in fair value of the deposit asset underlying the 10 % coinsurance agreement. For the nine months ended September 30, 2022, includes $( 3.4 ) million of net losses recognized for the change in fair value of the deposit asset underlying the 10 % coinsurance agreement. For the three and nine months ended September 30, 2021, includes $( 0.6 ) million and $( 1.6 ) million, respectively, of net losses recognized for the change in fair value of the deposit asset underlying the 10 % coinsurance agreement.

Investments - Net Investment _2

Investments - Net Investment Income (Parenthetical) (Details) - Deposit asset underlying 10% coinsurance agreement [Member] - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Schedule of Net Investment Income, Reported Amounts, by Category [Line Items]
Losses recognized for change in fair value of deposit asset underlying the 10% coinsurance agreement		$ (0.6)	$ (3.4)	$ (1.6)
Percentage of coinsurance costs	10%	10%	10%	10%
Maximum [Member]
Schedule of Net Investment Income, Reported Amounts, by Category [Line Items]
Losses recognized for change in fair value of deposit asset underlying the 10% coinsurance agreement	$ (0.1)

Investments - Schedule of Compo

Investments - Schedule of Components of Investment Gains (Losses) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Realized Investment Gains Losses [Abstract]
Gross gains from sales of available-for-sale securities fixed maturity securities	$ 491	$ 1,801	$ 1,512	$ 5,780
Gross losses from sales of available-for-sale fixed maturity securities	(199)	(71)	(588)	(2,018)
Realized investment gains (losses)	292	1,730	924	3,762
Credit losses impairment of available-for-sale securities	(138)	149	(57)	(710)
Market gains (losses) recognized in net income during the period on equity securities	(2,858)	(418)	(4,692)	1,117
Gains (losses) from bifurcated options		1		(48)
Gains (losses) on trading securities	5	(52)	(16)	(245)
Other investment gains (losses)	(2,991)	(320)	(4,765)	114
Investment gains (losses)	$ (2,699)	$ 1,410	$ (3,841)	$ 3,876

Investments - Schedule of Proce

Investments - Schedule of Proceeds from Sales or Other Redemptions of Available-For-Sale Securities (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Proceeds From Sale And Maturity Of Available For Sale Securities [Abstract]
Proceeds from sales or other redemptions	$ 117,909	$ 135,393	$ 419,985	$ 449,564

Investments - Accrued Interest

Investments - Accrued Interest - Narrative (Details)	9 Months Ended
	Sep. 30, 2022
Investments Debt And Equity Securities [Abstract]
Securities, description on accrued interest	Accrued interest is recorded in accordance with the original interest schedule of the underlying security. In the event of default, the Company’s policy is to no longer accrue interest on these securities and any remaining accrued interest will be written off. As a result, the Company has made the policy election to not record an allowance for credit losses on accrued interest.

Investments - Schedule of Secur

Investments - Schedule of Securities in Unrealized Loss Position (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value		$ 839,581
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses		(10,309)
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, fair value		70,909
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate losses		(3,561)
Fixed Maturities
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value	$ 1,950,731	764,334
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses	(215,363)	(10,305)
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, fair value	452,803	70,909
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate losses	(108,455)	(3,561)
Short-Term Investments
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value		75,247
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses		(4)
U.S. Government and Agencies [Member] | Fixed Maturities
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value	27,735	24,928
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses	(744)	(45)
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, fair value	2,170	1,557
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate losses	(236)	(34)
U.S. Government and Agencies [Member] | Short-Term Investments
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value		34,967
Foreign Government [Member] | Fixed Maturities
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value	114,843	18,894
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses	(7,332)	(384)
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, fair value	17,132	3,335
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate losses	(3,705)	(211)
Foreign Government [Member] | Short-Term Investments
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value		4,995
States and Political Subdivisions [Member] | Fixed Maturities
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value	105,750	15,909
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses	(18,900)	(254)
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, fair value	11,798
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate losses	(2,889)
States and Political Subdivisions [Member] | Short-Term Investments
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value		11,394
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses		(1)
Corporates [Member] | Fixed Maturities
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value	1,202,033	341,963
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses	(127,943)	(5,035)
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, fair value	239,948	59,414
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate losses	(66,308)	(3,033)
Corporates [Member] | Short-Term Investments
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value		23,891
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses		(3)
Residential Mortgage-backed Securities [Member] | Fixed Maturities
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value	301,304	234,911
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses	(41,127)	(3,131)
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, fair value	103,895	2,707
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate losses	(24,201)	(99)
Commercial Mortgage-backed Securities [Member] | Fixed Maturities
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value	96,986	47,220
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses	(10,949)	(419)
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, fair value	28,352	117
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate losses	(3,255)	(1)
Other Asset-backed Securities [Member] | Fixed Maturities
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value	102,080	80,509
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses	(8,368)	(1,037)
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, fair value	49,508	3,779
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate losses	$ (7,861)	$ (183)

Investments - Schedule of Sec_2

Investments - Schedule of Securities in Unrealized Loss Position (Parenthetical) (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses	$ 10,309
Maximum [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses	$ 1

Investments - Available-for-sal

Investments - Available-for-sale Securities with Cost Basis in Excess of Fair Value - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Investments Debt And Equity Securities [Abstract]
Available-for-sale fixed-maturities with cost basis in excess of fair values, cost basis	$ 2,700		$ 2,700		$ 924.4
Available-for-sale credit (gains) losses	$ (0.1)	$ (0.1)	$ (0.1)	$ 0.7

Investments - Rollforward of th

Investments - Rollforward of the Allowance for Credit Losses on Available-for-sale Securities (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Investments Debt And Equity Securities [Abstract]
Allowance for credit losses, beginning of period	$ 858	$ 816
Additions to the allowance for credit losses on securities for which credit losses were not previously recorded	6		$ 160
Additional increases or (decreases) to the allowance for credit losses on securities that had an allowance recorded in a previous period	(154)	(81)	550
Write-offs charged against the allowance, if any		$ (735)
Allowance for credit losses, end of period	$ 710		$ 710

Investments - Loss from Closed

Investments - Loss from Closed Currency Forward Contracts Recorded in Accumulated Other Comprehensive Income (Loss) - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net [Abstract]
Deferred loss related to closed forward contracts	$ (26.4)	$ (26.4)

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	$ 2,457,989	$ 2,702,567
Equity securities	33,079	42,551
Cash and cash equivalents	438,025	392,501
Separate account assets	2,206,608	2,799,992
Separate account liabilities	$ 2,206,608	2,799,992
Fair value assumptions, percentage of securities assessed by third-party pricing service	99%
Fair Value, Recurring Measurements [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	$ 2,457,989	2,702,567
Equity securities	33,079	42,551
Trading securities	3,718	24,355
Cash and cash equivalents	438,025	392,501
Separate account assets	2,206,608	2,799,992
Assets, fair value disclosure	5,139,419	6,047,209
Separate account liabilities	2,206,608	2,799,992
Liabilities, fair value disclosure	2,206,608	2,799,992
Fair Value, Recurring Measurements [Member] | Level 1 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	3,811	5,898
Equity securities	30,577	37,912
Cash and cash equivalents	438,025	351,508
Assets, fair value disclosure	472,413	395,318
Fair Value, Recurring Measurements [Member] | Level 2 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	2,448,008	2,696,642
Equity securities	988	1,070
Trading securities	3,718	24,355
Cash and cash equivalents		40,993
Separate account assets	2,206,608	2,799,992
Assets, fair value disclosure	4,659,322	5,648,295
Separate account liabilities	2,206,608	2,799,992
Liabilities, fair value disclosure	2,206,608	2,799,992
Fair Value, Recurring Measurements [Member] | Level 3 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	6,170	27
Equity securities	1,514	3,569
Assets, fair value disclosure	7,684	3,596
Fair Value, Recurring Measurements [Member] | U.S. Government and Agencies [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	31,738	32,400
Fair Value, Recurring Measurements [Member] | U.S. Government and Agencies [Member] | Level 2 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	31,738	32,400
Fair Value, Recurring Measurements [Member] | Foreign Government [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	139,944	152,976
Fair Value, Recurring Measurements [Member] | Foreign Government [Member] | Level 2 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	139,944	152,976
Fair Value, Recurring Measurements [Member] | States and Political Subdivisions [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	121,122	153,527
Fair Value, Recurring Measurements [Member] | States and Political Subdivisions [Member] | Level 2 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	121,122	153,527
Fair Value, Recurring Measurements [Member] | Corporates [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	1,475,832	1,713,684
Fair Value, Recurring Measurements [Member] | Corporates [Member] | Level 1 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	3,811	5,898
Fair Value, Recurring Measurements [Member] | Corporates [Member] | Level 2 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	1,472,021	1,707,786
Fair Value, Recurring Measurements [Member] | Residential Mortgage-backed Securities [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	412,026	375,631
Fair Value, Recurring Measurements [Member] | Residential Mortgage-backed Securities [Member] | Level 2 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	408,228	375,604
Fair Value, Recurring Measurements [Member] | Residential Mortgage-backed Securities [Member] | Level 3 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	3,798	27
Fair Value, Recurring Measurements [Member] | Commercial Mortgage-backed Securities [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	125,739	145,525
Fair Value, Recurring Measurements [Member] | Commercial Mortgage-backed Securities [Member] | Level 2 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	124,741	145,525
Fair Value, Recurring Measurements [Member] | Commercial Mortgage-backed Securities [Member] | Level 3 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	998
Fair Value, Recurring Measurements [Member] | Other Asset-backed Securities [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	151,588	128,824
Fair Value, Recurring Measurements [Member] | Other Asset-backed Securities [Member] | Level 2 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	150,214	128,824
Fair Value, Recurring Measurements [Member] | Other Asset-backed Securities [Member] | Level 3 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	1,374
Fair Value, Recurring Measurements [Member] | Short-Term Investments
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities		85,243
Fair Value, Recurring Measurements [Member] | Short-Term Investments | Level 2 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities		85,243
Fair Value, Recurring Measurements [Member] | Fixed-Maturity Securities and Short-term Investments [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	2,457,989	2,787,810
Fair Value, Recurring Measurements [Member] | Fixed-Maturity Securities and Short-term Investments [Member] | Level 1 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	3,811	5,898
Fair Value, Recurring Measurements [Member] | Fixed-Maturity Securities and Short-term Investments [Member] | Level 2 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	2,448,008	2,781,885
Fair Value, Recurring Measurements [Member] | Fixed-Maturity Securities and Short-term Investments [Member] | Level 3 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	$ 6,170	$ 27

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Rollforward of Level 3 Assets Measured on Recurring Basis (Details) - Fair Value, Recurring Measurements [Member] - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022		Sep. 30, 2021
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Level 3 assets, beginning of period		$ 1,634	$ 3,336	$ 3,596	[1]	$ 2,047	[1]
Net unrealized gains (losses) included in other comprehensive income		(8)	1	99	[1]	1	[1]
Realized gains (losses) and accretion (amortization) recognized in earnings		(127)	(125)	(328)	[1]	(359)	[1]
Purchases		6,170	2,068	13,661	[1]	3,067	[1]
Settlements		15	(1)	(1,385)	[1]	(2,191)	[1]
Transfers into Level 3	[1]			1,399		2,714
Transfers out of Level 3			(1,501)	(9,358)	[1]	(1,501)	[1]
Level 3 assets, end of period	[1]	$ 7,684	$ 3,778	$ 7,684		$ 3,778
[1] Activities for investments that enter and exit Level 3 in different quarters within the same fiscal year are not eliminated until the full year amounts are presented.

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair value security, level 1 to level 2 transfers, amount	$ 0	$ 0	$ 0	$ 0
Fair Value security, level 1 to level 3 transfers, amount	$ 0	$ 0	$ 0	$ 0

Fair Value of Financial Instr_6

Fair Value of Financial Instruments - Carrying Values and Estimated Fair Values of Financial Instruments (Details) - USD ($) $ in Thousands		Sep. 30, 2022	Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available-for-sale debt securities, at fair value		$ 2,457,989	$ 2,702,567
Fixed-maturity security held to maturity, fair value		1,320,222	1,551,113
Equity securities		33,079	42,551
Separate account assets		2,206,608	2,799,992
Surplus note		1,433,293	1,378,585
Separate account liabilities		2,206,608	2,799,992
Fixed-maturity security (held-to-maturity)		1,433,760	1,379,100
Reported Value Measurement [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available-for-sale debt securities, at fair value		2,457,989	2,702,567
Short-term investments (available-for-sale)			85,243
Equity securities		33,079	42,551
Trading securities		3,718	24,355
Separate account assets		2,206,608	2,799,992
Separate account liabilities		2,206,608	2,799,992
Reported Value Measurement [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Policy loans	[1]	48,787	30,612
Surplus note	[1],[2]	1,433,293	1,378,585
Fixed-maturity security (held-to-maturity)	[1]	1,433,760	1,379,100
Reported Value Measurement [Member] | Level 3 [Member] | Deposits [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Deposit asset underlying 10% coinsurance agreement	[1]	226,902	231,368
Reported Value Measurement [Member] | Level 2 [Member] | Senior Notes [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Notes payable - Long term	[2],[3]	592,705	592,102
Estimate of Fair Value Measurement [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available-for-sale debt securities, at fair value		2,457,989	2,702,567
Short-term investments (available-for-sale)			85,243
Equity securities		33,079	42,551
Trading securities		3,718	24,355
Separate account assets		2,206,608	2,799,992
Separate account liabilities		2,206,608	2,799,992
Estimate of Fair Value Measurement [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fixed-maturity security held to maturity, fair value	[1]	1,320,222	1,551,113
Policy loans	[1]	48,787	30,612
Surplus note	[1],[2]	1,316,919	1,545,854
Estimate of Fair Value Measurement [Member] | Level 3 [Member] | Deposits [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Deposit asset underlying 10% coinsurance agreement	[1]	226,902	231,368
Estimate of Fair Value Measurement [Member] | Level 2 [Member] | Senior Notes [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Notes payable - Long term	[2],[3]	$ 471,511	$ 605,667
[1] Classified as a Level 3 fair value measurement. Carrying value amounts shown are net of issuance costs Classified as a Level 2 fair value measurement.

Fair Value of Financial Instr_7

Fair Value of Financial Instruments - Carrying Values and Estimated Fair Values of Financial Instruments (Parenthetical) (Details)	Sep. 30, 2022	Dec. 31, 2021
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Percentage of coinsurance costs	10%	10%

Reinsurance - In-force Life Ins

Reinsurance - In-force Life Insurance (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Reinsurance Disclosures [Abstract]
Direct life insurance in-force	$ 915,091,729	$ 905,819,671
Amounts ceded to other companies	(782,367,621)	(777,826,233)
Net life insurance in-force	$ 132,724,108	$ 127,993,438
Percentage of reinsured life insurance in-force	85%	86%

Reinsurance - Narrative (Detail

Reinsurance - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Reinsurance Disclosures [Abstract]
Benefits and claims ceded to reinsurers	$ 375.8	$ 486.7	$ 1,218.8	$ 1,474.6

Reinsurance - Reinsurance Recov

Reinsurance - Reinsurance Recoverables and Financial Strength Ratings by Reinsurer (Details) - USD ($) $ in Thousands		Sep. 30, 2022	Dec. 31, 2021
Ceded Credit Risk [Line Items]
Reinsurance recoverables		$ 4,033,897	$ 4,268,419
Swiss Re Life & Health America Inc. (Novated from Pecan Re, Inc.) [Member] | AM Best, A+ Rating [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables	[1],[2]	2,474,068
Pecan Re Inc [Member] | External credit rating, not rated [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables	[1],[2]		2,567,602
SCOR Global Life Reinsurance Companies [Member] | AM Best, A+ Rating [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables	[3]	385,653	426,634
Munich Re of Malta [Member] | External credit rating, not rated [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables	[2],[4]	249,942	278,591
Swiss Re Life & Health America Inc. [Member] | AM Best, A+ Rating [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables	[5]	238,280	259,239
American Health and Life Insurance Company [Member] | AM Best, B++ Rating [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables	[2]	150,364	157,837
Munich American Reassurance Company [Member] | AM Best, A+ Rating [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables		134,059	142,705
RGA Reinsurance [Member] | AM Best, A+ Rating [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables		127,750	140,953
Korean Reinsurance Company [Member] | AM Best, A Rating [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables		119,526	134,048
Hannover Life Reassurance Company [Member] | AM Best, A+ Rating [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables		47,263	49,749
TOA Reinsurance Company [Member] | AM Best, A Rating [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables		36,590	38,909
All Other Reinsurers [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables		73,444	75,094
Allowance for Credit Losses [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables		$ (3,042)	$ (2,942)
[1] Effective April 1, 2022, the coinsurance agreement with Pecan Re Inc. was novated and replaced by an agreement with Swiss Re Life and Health America, Inc. Reinsurance recoverables includes balances ceded under coinsurance transactions of term life insurance policies that were in-force as of December 31, 2009. Amounts shown are net of their share of the reinsurance recoverables from other reinsurers. Arrangements with these reinsurers include collateral trust agreements held in support of reinsurance recoverables. Includes amounts ceded to Transamerica Reinsurance Companies and fully retroceded to SCOR Global Life Reinsurance Companies. Entity is rated AA- by S&P. Includes amounts ceded to Lincoln National Life Insurance and fully retroceded to Swiss Re Life & Health America Inc.

Reinsurance - Allowance for Cre

Reinsurance - Allowance for Credit Loss on Reinsurance Recoverable (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Reinsurance Disclosures [Abstract]
Balance, beginning of period	$ 2,964	$ 7,654	$ 2,942	$ 7,144
Current period provision for expected credit losses	78	0	270	510
Less: Recoveries from expected credit losses previously recorded	0	(53)	(170)	(53)
Balance, at the end of period	$ 3,042	$ 7,601	$ 3,042	$ 7,601

Policy Claims and Other Benef_3

Policy Claims and Other Benefits Payable - Schedule of Liability For Policy Claims and Other Benefits Payable (Details) - USD ($) $ in Thousands		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021
Roll Forward In Liability For Unpaid Claims And Claims Adjustment Expense [Abstract]
Policy claims and other benefits payable, beginning of period		$ 585,382	$ 519,711
Reinsured policy claims and other benefits payable, beginning of period		638,007	545,857
Net balance, beginning of period		(52,625)	(26,146)
Incurred related to current year		189,739	207,542
Incurred related to prior years	[1]	(3,383)	(121)
Total incurred		186,356	207,421
Claims paid related to current year, net of reinsured policy claims received		(236,246)	(276,730)
Reinsured policy claims received related to prior years, net of claims paid		66,047	36,439
Total paid		(170,199)	(240,291)
Foreign currency translation		(659)	44
Net balance, end of period		(37,127)	(58,972)
Reinsured policy claims and other benefits payable, end of period		533,690	616,097
Policy claims and other benefits payable, end of period		$ 496,563	$ 557,125
[1] Includes the difference between our estimate of claims incurred but not yet reported as of period-end and the actual incurred claims reported after period-end.

Stockholders' Equity - Reconcil

Stockholders' Equity - Reconciliation of Number of Shares of Common Stock (Details) - shares	1 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021
Stockholders Equity Note [Abstract]
Common stock, beginning of period		39,368,000	39,306,000
Shares issued for stock options exercised			10,000
Shares of common stock issued upon lapse of sales restrictions on restricted stock units (“RSUs”)		201,000	204,000
Common stock retired	(2,628,425)	(2,542,000)	(49,000)
Common stock, end of period	37,027,000	37,027,000	39,471,000

Stockholders' Equity - Narrativ

Stockholders' Equity - Narrative (Details) - USD ($) $ in Millions	1 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2022	Aug. 11, 2022	Feb. 14, 2022	Nov. 17, 2021
Class Of Stock [Line Items]
Stock repurchased program, authorized amount					$ 50	$ 50	$ 275
Stock repurchased and retired during period, shares	2,628,425	2,542,000	49,000
Stock repurchased and retired during period, value	$ 343.1
Stock repurchase program, remaining authorized repurchase amount	$ 31.9	$ 31.9
Forecast [Member]
Class Of Stock [Line Items]
Stock repurchased program, authorized amount				$ 375
Restricted stock units (RSUs) [Member]
Class Of Stock [Line Items]
Share-based compensation arrangement by share-based payment award, non-option equity instruments, outstanding, number	294,829	294,829
Performance share units (PSUs) [Member]
Class Of Stock [Line Items]
Share-based compensation arrangement by share-based payment award, non-option equity instruments, outstanding, number	74,054	74,054

Earnings Per Share - Calculatio

Earnings Per Share - Calculation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share [Abstract]
Net income (loss)	$ 51,807	$ 112,456	$ 241,172	$ 338,489
Income attributable to unvested participating securities, basic EPS	(244)	(458)	(1,067)	(1,403)
Net income used in calculating basic EPS	$ 51,563	$ 111,998	$ 240,105	$ 337,086
Weighted-average vested shares	37,438	39,561	38,342	39,516
Basic EPS	$ 1.38	$ 2.83	$ 6.26	$ 8.53
Income attributable to unvested participating securities, diluted EPS	$ (244)	$ (457)	$ (1,065)	$ (1,399)
Net income used in calculating diluted EPS	$ 51,563	$ 111,999	$ 240,107	$ 337,090
Dilutive effect of incremental shares to be issued for contingently-issuable shares	103	118	110	121
Weighted-average shares used in calculating diluted EPS	37,541	39,679	38,452	39,637
Diluted EPS	$ 1.37	$ 2.82	$ 6.24	$ 8.50

Share-Based Transactions - Impa

Share-Based Transactions - Impact of Equity Awards Granted (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity awards expense recognized	$ 1,060	$ 2,369	$ 16,068	$ 16,561
Expense Deferred [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity awards expense deferred	$ 2,691	$ 2,048	$ 7,878	$ 7,227

Share-Based Transactions - Narr

Share-Based Transactions - Narrative (Details) - $ / shares		3 Months Ended
	Feb. 24, 2022	Sep. 30, 2022
Restricted stock units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares awarded	85,844
Measurement date fair value	$ 130.3
Share-based compensation arrangement by share-based payment award, award vesting period	3 years
Restricted stock units (RSUs) [Member] | Etelequote Bermuda [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares awarded		10,711
Measurement date fair value		$ 125.65
Share-based compensation arrangement by share-based payment award, award vesting period		3 years
Performance share units (PSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares awarded	26,475
Measurement date fair value	$ 130.3
Share-based compensation arrangement by share-based payment award, award vesting period	3 years
Performance share units (PSUs) [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of PSUs vested during the period	39,713
Performance share units (PSUs) [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of PSUs vested during the period	0

Commitments and Contingent Li_2

Commitments and Contingent Liabilities - Narrative (Details) $ in Millions	Sep. 30, 2022 USD ($)
Letter of Credit [Member]
Commitments And Contingent Liabilities [Line Items]
Letter of credit, outstanding	$ 102.8

Other Comprehensive Income (Det

Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Foreign currency translation adjustments:
Change in unrealized foreign currency translation gains (losses) before income taxes	$ (18,086)	$ (5,892)	$ (24,048)	$ 6,490
Change in unrealized foreign currency translation gains (losses), net of income taxes	(18,086)	(5,892)	(24,048)	6,490
Unrealized gain (losses) on available-for-sale securities:
Change in unrealized holding gains (losses) arising during period before income taxes	(97,516)	(13,796)	(401,335)	(52,669)
Income tax expense (benefit) on unrealized holding gains (losses) arising during period	(20,471)	(2,991)	(85,330)	(11,653)
Change in unrealized holding gains (losses) on available-for-sale securities arising during period, net of income taxes	(77,045)	(10,805)	(316,005)	(41,016)
Reclassification from accumulated OCI to net income for (gains) losses realized on available-for-sale securities	(154)	(1,879)	(867)	(3,052)
Income tax (expense) benefit on (gains) losses reclassified from accumulated OCI to net income	(33)	(395)	(182)	(641)
Reclassification from accumulated OCI to net income for (gains) losses realized on available-for-sale securities, net of income taxes	(121)	(1,484)	(685)	(2,411)
Change in unrealized gains (losses) on available-for-sale securities, net of income taxes and reclassification adjustment	$ (77,166)	$ (12,289)	$ (316,690)	$ (43,427)

Debt - Narrative (Details)

Debt - Narrative (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Jul. 01, 2021
Debt Instrument [Line Items]
Amount withdraw From revolving credit facilities			$ 125,000,000
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 200,000,000	$ 200,000,000
Debt instrument maturity date		Jun. 22, 2026
Debt instrument, frequency of commitment fee payable		quarterly
Amount withdraw From revolving credit facilities	0	$ 0
Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	1,500,000,000	$ 1,500,000,000
Maximum [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument, commitment fee percentage		0.225%
Maximum [Member] | LIBOR Rate [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate margin		1.625%
Maximum [Member] | Base Rate [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate margin		0.625%
Minimum [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument, commitment fee percentage		0.10%
Minimum [Member] | LIBOR Rate [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate margin		1%
Minimum [Member] | Base Rate [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate margin		0%
Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 600,000,000	$ 600,000,000
Debt instrument, interest rate, stated percentage	2.80%	2.80%
Debt instrument maturity date		Nov. 19, 2031
Unsecured Subordinated Note [Member] | Etelequote Bermuda [Member]
Debt Instrument [Line Items]
Debt instrument, face amount				$ 15,000,000
Surplus Note [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 1,400,000,000	$ 1,400,000,000
Debt instrument, interest rate, stated percentage	4.50%	4.50%
Debt instrument maturity date		Dec. 31, 2030

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Summary of Disaggregation of Revenues from Contracts (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	$ 673,289	$ 693,239	$ 2,033,194	$ 1,985,638
Term Life Insurance Segment [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	427,830	401,451	1,256,967	1,167,016
Term Life Insurance Segment [Member] | Total Segment Revenues from Contracts with Customers [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	13,419	12,476	37,969	36,601
Term Life Insurance Segment [Member] | Total Segment Revenues from Contracts with Customers [Member] | Other, Net [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	13,419	12,476	37,969	36,601
Term Life Insurance Segment [Member] | Revenues from Sources Other Than Contracts with Customers (Segregated Funds) [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	414,411	388,975	1,218,998	1,130,415
Investment and Savings Products Segment [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	201,697	233,337	665,152	694,770
Investment and Savings Products Segment [Member] | Total Segment Revenues from Contracts with Customers [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	187,282	216,963	620,297	646,566
Investment and Savings Products Segment [Member] | Total Segment Revenues from Contracts with Customers [Member] | Other, Net [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	3,342	3,094	9,508	9,001
Investment and Savings Products Segment [Member] | Total Segment Revenues from Contracts with Customers [Member] | Commissions and Fees [Member] | Sales-based Revenues [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	67,962	95,229	259,905	298,057
Investment and Savings Products Segment [Member] | Total Segment Revenues from Contracts with Customers [Member] | Commissions and Fees [Member] | Asset-based Revenues [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	93,068	97,184	283,841	275,084
Investment and Savings Products Segment [Member] | Total Segment Revenues from Contracts with Customers [Member] | Commissions and Fees [Member] | Account-based Revenues [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	22,910	21,456	67,043	64,424
Investment and Savings Products Segment [Member] | Revenues from Sources Other Than Contracts with Customers (Segregated Funds) [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	14,415	16,374	44,855	48,204
Senior Health Segment [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	17,184	22,936	34,828	22,936
Senior Health Segment [Member] | Total Segment Revenues from Contracts with Customers [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	17,184	22,936	34,828	22,936
Senior Health Segment [Member] | Total Segment Revenues from Contracts with Customers [Member] | Other, Net [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	2,583	1,378	9,606	1,378
Senior Health Segment [Member] | Total Segment Revenues from Contracts with Customers [Member] | Commissions and Fees [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	14,601	21,558	25,222	21,558
Corporate and Other Distributed Products Segment [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	26,578	35,515	76,247	100,916
Corporate and Other Distributed Products Segment [Member] | Total Segment Revenues from Contracts with Customers [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	14,133	19,098	40,716	50,180
Corporate and Other Distributed Products Segment [Member] | Total Segment Revenues from Contracts with Customers [Member] | Other, Net [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	1,621	1,103	3,626	2,978
Corporate and Other Distributed Products Segment [Member] | Total Segment Revenues from Contracts with Customers [Member] | Commissions and Fees [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	12,512	17,995	37,090	47,202
Corporate and Other Distributed Products Segment [Member] | Revenues from Sources Other Than Contracts with Customers (Segregated Funds) [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	$ 12,445	$ 16,417	$ 35,531	$ 50,736

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Summary of Renewal Commissions Receivable (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Senior Health Segment [Member]
Disaggregation Of Revenue [Line Items]
Balance, beginning of period		$ 134,212		$ 172,308
Contract balances acquired as part of business combination			$ 199,575		$ 199,575
Measurement period adjustment	[1]			(11,863)
Commissions revenue		9,600	16,526	32,011	16,526
Less: collections		(8,808)	(6,842)	(33,032)	(6,842)
Tail revenue adjustments from change in estimate		1,700		(22,720)
Balance, at the end of period		136,704	209,259	136,704	209,259
Corporate and Other Distributed Products Segment [Member]
Disaggregation Of Revenue [Line Items]
Balance, beginning of period		59,449	56,683	59,443	54,845
Commissions revenue		7,908	8,810	19,833	21,969
Less: collections		(6,034)	(5,800)	(17,953)	(17,121)
Balance, at the end of period		$ 61,323	$ 59,693	$ 61,323	$ 59,693
[1] The measurement period adjustment was recorded during the nine months ended September 30, 2022 in order to finalize the purchase price allocation for the acquisition of e-TeleQuote. Refer to Note 14 (Acquisition) for further details.

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Narrative (Details)	Sep. 30, 2022 USD ($)
Revenue From Contract With Customer [Abstract]
Assets recognized for incremental costs	$ 0

Acquisition - (Narrative) (Deta

Acquisition - (Narrative) (Details) - USD ($)			9 Months Ended
	Jul. 01, 2022	Jul. 01, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Business Acquisition [Line Items]
Payments to Acquire Business			$ (3,867,000)	$ 494,459,000
Goodwill			$ 127,707,000		$ 179,154,000
Etelequote Bermuda [Member]
Business Acquisition [Line Items]
Business acquisition, date of acquisition agreement		Jul. 01, 2021
Percentage of interest acquired		80%
Percentage of voting interests acquired		100%
Amount paid-off in acquisition		$ 146,000,000
Payments to Acquire Business	$ 0	$ 350,000,000
Percentage of common stock issued and outstanding		20%
Cash consideration		$ 3,900,000
Remaining percentage of interest acquired	20%
Business acquisition, effective date of acquisition	Jul. 01, 2022
Business combination, recognized identifiable assets acquired and liabilities assumed, intangible assets		156,000,000
Goodwill		263,706,000
Etelequote Bermuda [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, intangible assets		$ 153,000,000
Estimated useful life		15 years
Etelequote Bermuda [Member] | Unsecured Subordinated Note [Member]
Business Acquisition [Line Items]
Debt instrument, face amount		$ 15,000,000

Acquisition - Summary of Identi

Acquisition - Summary of Identified Assets Acquired and Liabilities Assumed at Acquisition Date (Details) - USD ($) $ in Thousands		Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021	Jul. 01, 2021
Assets:
Goodwill		$ 127,707		$ 179,154
Etelequote Bermuda [Member]
Assets:
Cash and cash equivalent					$ 1,080
Accounts receivables					303
Renewal commissions receivable					141,584
Other assets					15,705
Intangible assets					156,000
Goodwill					263,706
Total assets					578,378
Liabilities:
Accounts payable and accrued expenses					4,590
Deferred tax liability					48,633
Other liabilities					10,046
Total liabilities					63,269
Net assets acquired					515,109
Temporary Stockholders' Equity:
Redeemable noncontrolling interests					8,437
Total temporary stockholders' equity					8,437
Etelequote Bermuda [Member] | Preliminary Purchase Price Adjustment [Member]
Assets:
Cash and cash equivalent					1,080
Accounts receivables					692
Renewal commissions receivable					199,575
Other assets					15,705
Intangible assets					162,000
Goodwill					224,180
Total assets					603,232
Liabilities:
Accounts payable and accrued expenses					8,785
Deferred tax liability					65,425
Other liabilities					10,046
Total liabilities					84,256
Net assets acquired					518,976
Temporary Stockholders' Equity:
Redeemable noncontrolling interests					8,437
Total temporary stockholders' equity					$ 8,437
Etelequote Bermuda [Member] | 2021 Measurement Period Adjustments [Member]
Assets:
Accounts receivables				(389)
Renewal commissions receivable				(46,128)
Intangible assets				(6,000)
Goodwill				30,973
Total assets				(21,544)
Liabilities:
Accounts payable and accrued expenses	[1]			(4,195)
Deferred tax liability				(13,482)
Total liabilities				(17,677)
Net assets acquired				$ (3,867)
Etelequote Bermuda [Member] | 2022 Measurement Period Adjustments [Member]
Assets:
Renewal commissions receivable			$ (11,863)
Goodwill			8,553
Total assets			(3,310)
Liabilities:
Deferred tax liability			(3,310)
Total liabilities			$ (3,310)
[1] The Company also recognized an adjustment during the measurement period to reclassify certain amounts from a payable to a reduction in the renewal commissions receivable.

Goodwill - (Narrative) (Details

Goodwill - (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill impairment loss	$ 60,000	$ 60,000
Goodwill	127,707	127,707	$ 179,154
Accumulated goodwill impairment charges	$ 136,000	$ 136,000